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CHAPTER I 
INTRODUCTION 
1.1. Characteristics of the mouse mammary tumour virus 
Development of mouse mammary tumours is a complex phenome-
non, to which environmental factors, genetic background and 
the presence of an oncovirus contribute. 
The mammary tumour virus (MTV) of the mouse, first dis-
covered by Bittner (1936), is a so-called B-type particle 
(Bernhard, 1958) and is composed of two major distinguish-
able elements {Sarkar et al., 1971): a bilayer lipid mem-
brane whose exterior surface is covered with knobbed pro-
jections and a viral core. The virus consists of at least 
11 different polypeptides; two of the major proteins are 
glycoproteins with molecular weights of 45,000 to 55,000 
and 34,000 to 36,000 Daltons (D); they are usually referred 
to as gp52 and gp36. The knobs of the viral projections are 
composed of gp52; the gp36 component is situated within the 
membrane from which the projections protrude. Three other 
major polypeptides with molecular weights of approximately 
28,000 (p28), 18,000 (p18) and 12,000 (p12) D are associ-
ated with the viral core. The main group-specific antigens 
are gp52 and p28 (Sarkar and Dion, 1975; Sarkar et al., 
1976). 
The infected mouse mammary tumour cells release mature MTV 
particles in the intercellular spaces: the RNA-containing 
core moves into contact with the cell membrane to begin an 
enveloping process, at the conclusion of which mature MTV-
particles bud off from the cell membrane. Intracytoplasma-
tic type-A particles (iAp) which are also present in mouse 
mammary tumour cells are considered to be the immature core 
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component of MTV (Bernhard, 1960). This is likely since B 
and A particles share common antigens (Tanaka et al., 1972; 
Zotter et al., 1976); also, it has been found that after 
trypsinization of iAp the polypeptides of MTV emerge (Smith 
and Lee, 1975). 
It is generally assumed that, in analogy with the Rous sar-
coma virus (Baltimore, 1975), the RNA genome of MTV con-
tains at least four genes. The so-called ''gag" gene codes 
for the core proteins. ''Gag'' is an abbreviation of group-
specific antigens; since not all core proteins are group-
specific, this name is, although generally used, not cor-
rect. The "pol" gene codes for the RNA dependent DNA poly-
merase, the so-called reverse transcriptase. The envelope 
proteins are coded for by the ''env''-gene, and the ''one'' 
gene codes for the oncogenic properties of the virus. 
The ''env''-gene products, so the structural viral enve-
lope proteins, are expressed on the tumour cell membrane. 
The "one" gene products are not yet clearly characterized, 
and are most likely nonstructural virion proteins. In some 
oncovirus systems, there are indications that the proteins 
coded for by the ''one'' gene are expressed on the tumour 
cell membrane in the form of tumour specific cell surface 
antigens [TSSA('s)]. When this model is applied to the 
MTV-system, the situation will be as is shown in Figure l. 
There are three known modes of natural transmission of MTV 
in mice: 
a) horizontal transmission: the MTV is introduced into 
the mouse strain by the maternal milk (Bittner, 1936); 
b) vertical transmission; MTV is presen~ as a provirus 
in the cellular genomes (Bentvelzen and Daams, 1969). 
c) congenital transmission. Occasionally in utero 
infection of the zygote by virus in the seminal fluid 
takes place (Andervont, 1963). Despite several trials, 
until now no evidence has been found for transplacental 
transmission of virus (Zeilmaker, 1969). 
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Figure 1: 
Hypothetical model of MTV-expression 
A B-type particle with the RNA genome, containing four genes: the "gag"-
gene, coding for the core proteins p28, p18, and p12; the ''pol"-gene, 
coding for the viral polymerase, ''retra''; the ''env"-gene, coding for 
the viral envelope genes gp52 and gp36; and the "onc"-gene, coding for 
the oncogenic properties of the virus. The products of the "env"-gene 
and possibly also those of the "onc"-gene [TSSA( 's)] are expressed on 
the tumour cell membrane. 
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Table 1. 
ENDOGENOUS AND EXOGENOUS MTV OF SEVERAL MOUSE STRAINS* 
mouse strain M'rv 
endogenous exogenous 
C3Hf*** MTV-L 
-
C3H MTV-L MTV-S 
BALB/c MTV-0 -
BALB/cfC3H MTV-0 MTV-S 
GR MTV-P -
RIIIf ? -
RIII ? MTV-PS 
Af MTV-L -
A MTV-L MTV-SV 
DBAf MTV-L -
* 
** 
P. Bentvelzen, 1975; unpublished results 1975-1977. 
See text {page 12) 
virulence** 
avg. 
mice 
+ 
++++ 
++++ 
++++ 
+++ 
? 
++++ 
+ 
+++++ 
+ 
tumour induction 
age of incidence 
{weeks) {2:) 
77 15 % 
31 100 % 
77 30 % 
36 100 % 
27 100 % 
82 10 % 
42 90 % 
87 20 % 
18 100 % 
*** f only stands for foster-nursing on a mouse strain that lacks exogenous virus; when a virus is 
introduced into a given mouse strain by foster nursing, the strain of the foster mother is also 
given. 
One mouse strain can harbour several substrains of 
MTV, each of which may be transmitted in a different 
manner. 
1. 2. lvJTV expression and mammo:J'y tumour development in different mouse 
studies 
Various mouse strains have been shown to have their own 
strain-specific MTV variant with its own characteristic 
expression, virulence, host range and mode of transmis-
sion. Table 1 summarizes these properties for several MTV 
variants. 
Except for MTV-P, all virus strains listed in this 
table induce tumours that show a hormone-independent 
growth. The exogenous viruses are all transmitted by the 
the maternal milk. Except for MTV-P, which is transmitted 
by both the milk and the gametes, all endogenous viruses 
are heriditarily acquired. 
Virulent MTV strains induce 100 % mammary tumours be-
fore one year of age when injected into a 4-5-week-old sus-
ceeptible host; less virulent strains have a longer incuba-
tion period. When neonatally or heriditarily acquired, all 
virulent MTV strains induce a high tumour incidence at a 
relatively young age in their relevant mouse strains, ex-
cept for MTV-0, which as far as spontaneous tumours are 
concerned, only causes a moderate tumour incidence in old 
retired breeders. MTV-L causes a low tumour incidence in 
very old mice. 
The tumour incidences given here are obtained from ani-
mals that were subjected to forced breeding; the resulting 
hormonal stimulation promotes the development of mammary 
tumours (Bentvelzen, 1975; unpublished results 1975-1977). 
Biochemical evidence for the presence of endogenous viruses 
has been provided by molecular hybridization studies: when 
MTV is transmitted vertically, the cellular DNA of all so-
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matic cells should contain the complete proviral sequences 
of this MTV. In the GR mouse strain that carries the to 
contain identical information (Drohan et al., 1977). DNA of 
C3H mouse mammary tumours that are induced by the exogenous 
MTV-S also contain additional proviral MTV-S sequences; 
however, in the liver these sequences are lacking. The 
exogenous proviral sequences of MTV-S differ 25 % from the 
endogenous MTV-L DNA sequences (Michalides et al., 1976). 
Nevertheless, infectious MTV-S could be retrieved from the 
salivary gland, kidney, testis and epidydimus of male 6-
month-old BALB/cfC3H mice (Bentvelzen and Brinkhof, 1976). 
This indicates that, besides the mammary gland, also 
several normal organs are infected by the exogenous virus 
in the neonatal period. Expression of MTV antigens in 
normal organs is found in 6-month-old animals of the 
BALB/cfC3H and GR strains, but not in the BALB/c and C3Hf 
strains (Haaijman, 1977). 
Female mice of the BALB/cfC3H, GR, C3H, A and RIII 
strains all produce high levels of MTV in the milk at a 
young age; these strains are therefore considered as high 
MTV expressers. Mouse strains that produce only moderate 
amounts in their milk at a late age (Af, C3Hf, DBAf, BALB/c 
and RIIIf) are referred to as low MTV expressers. 
When no tumour is present, blood plasma levels of gp52 
are low in males and females of both high- and low-MTV-
expressing strains. The gp52 levels are not affected by 
lactation. Only shortly before the tumour becomes clinical-
ly detectable does the level increase (Ritzi et al., 1976). 
On mammary tumour cells, MTV-antigens are not restricted to 
budding B-particles but are also present on other sites of 
the plasma membranes (Calafat et al., 1974). Recently, 
specific antisera against the MTV polypeptides gp52, p28 and 
pl2 became available in our laboratory and three cell lines 
were tested for the presence of these antigens on the cell 
membrane: the virus-producing C3H derived cell line called 
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C3HMT/cl.ll, the MTV-P producing GR mouse ascitis leukaemia, 
called GRSL and the DEAf MTV-containing Ll210 ascites leu-
kaemia. All cell lines expressed gp52 and to a lesser ex-
tent pl2 on the membranes, but no clear-cut evidence for 
the expression of p28 on mammary tumour cell membranes 
could be found (Westenbrink et al., 1978). 
On incubation with anti-MTV-antiserum, mammary tumour 
cells show antigenic redistribution and subsequent shedding 
of the MTV antigens from the cell surface; normal tissue 
antigens on these tumour cells did not show this phenomenon 
(Calafat et al., 1976). This finding will have serious con-
sequences for the effectiveness of the immune reaction of 
the animals, since tumour antigens in a soluble form will 
compete with the tumour for the immune effector processes 
(Alexander, 1974). 
1. 3. Immunity to MTV in healthy animals 
Although it has been a widely held opinion for a long time 
that healthy mice are immunologically tolerant to endoge-
nous and exogenous oncoviruses, this concept has been 
challenged by several recent reports which demonstrate the 
occurrence of natural immune responses to these viruses. 
In the MTV system, spontaneously occurring antibodies 
reacting specifically to MTV have been demonstrated in 
tumour-free animals in strains with a high mammary tumour 
incidence. Some authors also describe the appearance of 
antibodies in female tumour-free mice in strains with a low 
tumour incidence (Muller et al., 1971). The concentration 
of antibodies increases with age (Ihle et al., 1976). In 
addition, the occurrence of natural antibodies against iAp 
has been reported (Zotter and Muller, 1977). 
MTV-specific cellular immunity has also been observed in 
mice long before the onset of tumour growth. Very extensive 
investigations have been performed by Blair {1976) with the 
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rnicrocytotoxicity assay in BALB/cfC3H and BALB/c mice. Ac-
cording to her findings, spleen cells of BALB/cfC3H mice be-
come reactive within one month after birth. This response is 
mediated by T cells. She also observes antibody-dependent 
cell-mediated cytotoxicity (ADCC) mediated by null cells and 
factors which block the T cell mediated target cell lysis. 
BALB/c mice become reactive only after four months; she 
postulates that this response is initiated by horizontal 
transmission of the exogenous MTV-S. 
It must be taken into account, however, that the micro-
cytotoxicity assay performed in microtiter plates is techni-
cally cumbersome and not very reliable (Howell et al., 1974; 
Brown et al., 1976). Moreover, Blair's results could not be 
repeated in several laboratories, including our own (unpub-
lished results). Therefore the relevance of these findings 
remains unclear. 
In contrast to Blair, Lopez et al. (1976) and Sigel et 
al. (1976), who measured reactivity with lymphocyte stimu-
lation and migration inhibition assays, report that BALB/c 
mice are reactive, whereas BALB/cfC3H mice fail to respond; 
for the latter, they suggest a form of unresponsiveness, 
since lack of reactivity can be changed to reactivity by a 
tumour implant. This is in accord with the findings of 
Gillette and Lowrey (1976) with a cytostasis assay. They 
found that reactivity was greater in lymphoid cells from low 
MTV expressers than in syngeneic high MTV expresser strains. 
Newborns were all negative. Although cytostasis was not me-
diated by theta-positive cells, cells from nude athymic 
donors did not respond; they conclude therefore that T 
cells are required for the initiation of this form of anti-
MTV-immunity. 
Although all authors agree that immune responses in tumour-
free animals are much lower than in tumour bearing mice, it 
can be concluded from these findings that mammary tumours 
progress in the face of a significant response to MTV-in-
duced antigens. 
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1.4. Immunity to MTV in tumour-bearing animals 
There are many reports on the presence of precipitating 
antibodies to MTV in mice bearing palpable tumours. Results 
with radioimmunoassay (RIA) (Ihle et al., 1976) revealed 
much higher titers in tumour-bearing C3H females than in 
normal animals. Muller et al. (1971) also found that, ex-
cept for the GR strain, more tumour bearing than normal 
animals had anti-MTV antibodies in their serum. Immune com-
plex deposits have been found in the glomeruli of tumour 
bearing RIII mice (Pascal et al., 1975). 
Stolfi et al. (1975) detected that sera from tumour 
bearers express complement-dependent cytotoxic activity, 
but only when high dilutions were used. They postulate that 
at low dilutions the cytotoxic reaCtion is prevented by an 
inhibitor, but have not investigated this further. 
With respect to cellular immunity to MTV in tumour bearers, 
Blair (1976), using the microcytoxicity assay, gives an 
extremely complex picture: In BALB/cfC3H mice, the ADCC 
becomes undetectable during tumour growth and is not found 
in females bearing large progressively growing tumours. The 
factors that block T cell activity remain in the circula-
tion: in addition, 2 other serum factors become detectable: 
a) a factor that blocks ADCC; and b) an antibody not 
directed to MTV but tumour-specific, which recruits normal 
cells to cytotoxicity. Also for these results, however, the 
considerations concerning the ro.producibility of this test 
must be taken into account (page 16). In two almost comple-
tely identical articles (Roubinian et al., 1976; Roubinian 
and Blair, 1977), this group also reports that tumour 
growth is inhibited by incomplete thymectomy, whereas com-
plete removal of the thymus leads to promotion of tumour 
growth. Besides T cell dependency of the anti-MTV-reaction, 
this also points to the presence ofT suppressor cells. 
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Sigel et al. (1976) and Lopez et al. (1976) found 
higher MTV-specific migration inhibition and leukocyte 
stimulation reactions in tumour bearers than in normal 
animals. They do not mention a change in reactivity during 
tumour growth. This group also reports on the emergence of 
a complement-receptor-positive T cell population during 
development of the tumours {Epstein eta!., 1976). 
In the investigation reported in this thesis, the observa-
tion concerning the T cell dependency of anti-MTV and anti-
tumour cell cellular immune reactivity was confirmed. 
During the study of cell-mediated immune reactions in 
tumour-bearing mice, it became evident that this reactivity 
declines gradually during tumour growth and becomes se-
verely impaired. In Gross leukaemia virus and Moloney sar-
coma virus induced tumour systems, this immune deficiency 
was caused by cells with adherent properties, which sup-
pressed cell proliferation induced by stimulation with 
plant lectins (Kirchner et al., 1974; 1975; Glaser et al., 
1975). Kruisbeek and Van Hees (1977) observed this 
phenomenon in rats bearing transplanted bladder carcinomas. 
In the MTV system, we found such suppressor cells inhibit-
ing MTV-specific cell proliferation. However, in spleen 
cell suspensions of animals bearing large tumours removal 
of these suppressor cells was not sufficient to restore the 
specific anti-MTV reactivity. Also, fluctuations in the 
inhibition by the suppressor cells during tumour growth did 
not show a reverse correlation with the variation in the 
responsiveness of lymphoid cells. The decline in cellular 
reactivity to MTV during tumour growth must therefore also 
be due to other factors. 
In various systems, it has been shown that nonrespon-
siveness of lymphoid cells during tumour growth can be 
eliminated by either slight trypsinization or extensive 
washing of the cells (Battler and Soehnlen, 1974; Kjaer, 
1976; Grosser and Thompson, 1976). In this study, these 
procedures have been successfully applied to restore 
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reactivity to MTV. In addition, the presence of serum 
factors that block cellular reactivity has been estab-
lished. The possible nature of these inhibiting factors was 
investigated. 
1.5. Vaccination experiments 
Several populations of chickens show a very high incidence 
of lymphoma's (Marek's disease); they can be completely 
protected by vaccination with the attenuated causative 
herpes virus. It is highly interesting to know whether this 
approach is also useful for prophylaxis of tumours caused 
by RNA oncoviruses. 
Until recently, most vaccination studies have been 
performed with inactivated malignant cells or whole virus. 
However, there is widespread concern about the dangers of 
introducing materials that may contribute to the develop-
ment of neoplasms. For this reason vaccination studies on 
oncoviruses focus more and more on purified viral subunit 
proteins. 
Successful vaccination is still difficult to achieve. 
Despite a large number of trials with malignant cells, 
oncoviruses and viral subunits, this has resulted in only a 
few successes in terms of tumour prophylaxis. In view of 
the existence of natural immunity against many oncoviruses, 
this is not surprising: immunization in these cases re-
presents an alteration of an existing immune status rather 
than induction of immunity. 
Promising results have been described for vaccination 
against feline leukaemia virus (FeLV) in cats: protection 
against challenge with live virus has been achieved with 
feline oncovirus associated cell membrane antigen (FOCMA) 
and with ultraviolet (UV) light inactivated feline sarcoma 
virus (FeSV) (Jarrett et al., 1975). Hunsmann et al. (1975) 
report that vaccination of a low-leukaemic mouse strain 
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with the purified major surface glycoprotein gp71 of Friend 
leukaemia virus (FLV) resulted in significant lower spleen 
weights after a later virus challenge in treated animals as 
compared to control mice. 
It was later on reported, however, that mice immunized 
with FLV are resistant to a subsequent virus challenge only 
when they have become infected with the FLV-associated 
lymphatic leukaemia virus (Bendinelli, 1977). The authors 
reporting on FeLV and FLV all claim that protection was 
associated with high antibody titers. 
In other oncoviral systems, however, attempts at vac-
cination led to a more pessimistic attitude. Gross leukae-
mia virus-induced tumours in rats showed a significantly 
enhanced growth following sensitization to soluble tumour 
antigen; this was associated with a depression of cell-
mediated immunity (Rao and Bonavida, 1976). A KCl extract 
derived from a murine tumour cell line containing both 
Moloney leukaemia virus and Moloney sarcoma virus had both 
immunogenic and immunosuppressive capacities (Brandschaft 
et al., 1976). 
In the MTV system, several attempts have been made to vac-
cinate mice with mammary tumour cells as well as with 
purified virus preparations. Injection of mammary tumour 
cells which were inactivated by X-radiation into C3Hf mice 
that had been surgically cured of a mammary tumour resulted 
in specific protection against later tumour challenge 
(Vaage and Agarwal, 1976). Injection of an extract from a 
C3Hf-derived tumour cell line containing TSSA led to a 
reduction in spontaneous tumour development in C3Hf mice 
(Irie and Irie, 1971). 
The first indications that vaccination may be compli-
cated by suppressive immune mechanisms emerged when it was 
found that immunization with mammary tumour tissue or virus 
and complete Freund 1 S adjuvant (FA) lead to the accelerated 
appearance of spontaneous tumours in neonatally infected 
mice (Hinsch and Iversen, 1961; Bentvelzen et al., 1970). 
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Tumour growth enhancing phenomena were also observed when 
the influence of a derivative of BCG, called MER, was 
tested: treatment with MER alone prior to tumour trans-
plantation caused acceleration of tumour growth in BALC/cf 
C3H and BALB/c mice. MER treatment combined with specific 
tumour immunization did not result in enhancement of tumour 
development. However this combined treatment had no added 
beneficial effect over immunization with tumour alone 
(Jacobs and Kripke, 1974). 
When purified MTV preparations are used, protection 
against tumour development is almost uniformly reported: 
Formalinized MTV-S with or without FA gives protection in 
BALB/c mice (Burton et al., 1969). Inoculations with live, 
formalinized or ether-treated MTV-S preparations in GR mice 
at the age of 4 - 7 weeks all delayed tumour development; 
vaccination at a later age gave less protection. Live MTV-P 
had no effect, in contrast to H2o 2-treated MTV-P prepa-
rations (Vander Gugten and Bentvelzen, 1969). Formalinized 
RIII virus resulted in protection against spontaneous 
tumours in the low-MTV-expressor RIIIf and Af mouse 
strains. A dose of 1 pg in combination with FA protected 
C57BL mice against later RIII virus challenge (Charney et 
a1., 1976). 
Stutman (1976) reports a moderate protective effect in 
both C3H and C3Hf mice after vaccination with formalinized 
MTV; however, when soluble antigens extracted from C3H mam-
mary tumours were used, there was an acceleration of tumour 
appearance. 
We are presently engaged in a study concerning tumour pro-
phylaxis by use of MTV subunit protein vaccines and have 
obtained protection using low doses of an MTV protein frac-
tion that was enriched for gp52. 
For the development of a suitable vaccination proce-
dure, we first investigated the induction of transplanta-
tion resistance to MTV-containing neoplasms. We used BALB/c 
mice which were challenged with MTV-0-containing mammary 
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tumours and DBA£ mice which were challenged with the MTV-
containing Ll210 ascitic leukaemia (Radzikowski et al., 
19 72). 
As an adjuvant, we used alum, which is known to enhance 
antiviral immunity (Mautner and Willcox, 1974), and an 
interphase material ( IPM) isolated from MycobacterivM smegmatis 
which has a considerable antitumour activity in itself 
(Lamensans et al., 1975). 
Cellular and humoral immune responses to MTV were moni-
tored in order to obtain insight into the immune mechanisms 
evoked by the different vaccination procedures. 
In the view of the protection against transplanted 
tumour cells that occurred after vaccination with a low 
dose of the MTV-protein fraction, we studied the influence 
of a low fixed dose (lOpg) of this vaccine on primary 
tumour development in the BALB/c, C3H, BALB/cfC3H and GR 
strains. In addition, in BALB/cfC3H mice we studied the in-
fluence of the administration of booster doses on primary 
tumour development. 
1.6. Rationale for the investigation: relation of the mouse model to 
human breast cancer 
The lack of rejection of breast tumours in both man and 
mice is most probably due to an insufficient response of 
the immune system. A main reason for studying the immune 
response to mammary tumour antigens in mice is to obtain 
some insight into problems concerning immune therapy of 
humans suffering from breast cancer, or vaccination of high 
risk groups. Therefore, antigenic and epidemiological 
relatedness between mouse MTV and human breast cancer 
antigens is of utmost importance. 
The first evidence for possible involvement of an once-
virus in human breast cancer was found in 1974 when McGrath 
et al. and Lasfarques and Moore detected virus-like par-
ticles, as well as reverse transcriptase in human breast 
cancer cell lines. The particles showed cross-reactivity to 
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MTV {McGrath et al., 1974). Zachrau et al. {1976) presented 
evidence that approximately 65 % of human breast cancer 
tissues contained a prominent protein fraction with a 
molecular weight of 47,000 to 55,000 D, whereas such com-
ponent could not be found in benign breast tissue. An indi-
cation for an epidemiological similarity between MTV in 
mice and the human breast cancer particle is provided by 
the finding of particles in milk from apparently healthy 
humans ( ~1oore et al., 19 70). The major core protein of 
these particles has a molecular weight of 27,000 D and is 
electrophoretically identical to the major core protein of 
MTV {Furmanski et al., 1976). 
There is some evidence that in human breast cancer also 
particles related to Mason-Pfizer monkey virus (MPMV) occur: 
the RNA of human breast cancer particles possess detectable 
homology to the RNA of MTV {Axel et al., 1972) and of MPMV 
(Colcher et al., 1974). Also the purified reverse trans-
criptase of the human breast cancer particle cross-reacts 
immunologically with the MPMV enzyme (Ohno and Spiegelman, 
1977). 
Other evidence for antigenic relationships between MTV pro-
teins and those of the human breast cancer particle is 
provided by immunological studies: Muller et al. (1976) 
detected antibodies in the sera of breast cancer patients 
which were specifically reactive to iAp in mouse mammary 
tumour cells. 
Fifty per cent of breast cancer patients and 25 % of 
normal woman harbour lymphoid cells that react to Rill 
mouse milk (Cunningham-Rundles et al., 1976); this reacti-
vity was associated with preferential cross-reactivity to 
C3H-MTV and human autologous and homologous breast cancer 
tissue that contained gp55 resembling mouse MTV gp52. 
Minimal cross reactivity was found with gpSO from strain A 
MTV, RLV and with human breast cancer tissue that had no 
mouse MTV-gp52-like protein {Black et al., 1976). By means 
of membrane immunofluorescence with anti-MTV gp52 anti-
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serum, gp52 could be demonstrated on peripheral lymphocytes 
of 14 out of 20 breast cancer patients, while only 2 of 10 
normal agematched women had reactive lymphocytes (Wiseman 
et al., 1977). 
Another characteristic shared by the cell surface anti-
gens of mouse and human mammary tumour cells is the pheno-
menon of antigenic modulation: upon incubation with an 
antiserum specifically reactive to human breast cancer 
antigens, breast cancer cells show redistribution of 
antigens and subsequent shedding of these antigen-antibody 
complexes (Nordquist et al., 1977). 
For a rational approach to specific immune manipulation, it 
is necessary to know the cause of the derailment of the 
immune reaction during tumour growth. Therefore, we first 
studied the immune response to MTV in tumour-bearing mice. 
During these studies, we found immunological indicators 
that were relevant for tumour survival in untreated mice. 
Besides measuring the resistance to primary and trans-
planted tumours, these indicators were used to evaluate the 
effectiveness of several vaccination schemes. 
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CHAPTER II 
TECHNICAL APPROACH 
2.1" Animals 
The following inbred mouse strains were used for the 
studies reported here: 
GRS 11/A Rij £, further referred to as GR. Genetics: c, 
H-2dx. Origin: Gr nder, in 1955 to Amsterdam, in 1969 to 
Rijswijk. Inbreeding generation at the Radiobiological 
Institute (RBI), Rijswijk: F2l-F24. 
C3Hf/Lw Rij f, further referred to as C3Hf. Genetics: 
+, H-2k. Origin: 1920 Strong, in 1930 to Andervont, in 
1941 to Heston, to Law, in 1965 to Rijswijk. Inbreeding 
generation at RBI: F38-F41. 
BALB/c AN Crl Rij f, further referred to as BALB/c. 
Genetics: b, c, H-2d. Origin: 1913 Bagg, in 1923 to 
McDowell, in 1932 to Snell, to Andervont, to ?, to Battelle 
Memorial Institute, in 1966 to Charles River Laboratories, 
in 1968 to Rijswijk. Inbreeding generation at the RBI: F25-
F2 8. 
BALB/c foster nursed on C3H, further referred to as 
BALB/cfC3H. This mouse strain has been established in our 
laboratory in 1970 by Dr. P. Bentvelzen. 
DBA/2 f, further referred to as DBA£. Genetics: un-
known. Origin: from Law, in 1962 to the Medical Biological 
Laboratory, Rijswijk, from which we received these mice. 
C57BL/Ka Lw Rij f, further referred to as C57BL. Genet-
ics: a, H-2b. Origin: 1921 Little, to Strong, in 1947 to 
Kaplan, to Law, in 1965 to Rijswijk. Inbreeding generation 
at RBI: F30-F33. 
All strains were conventional from a gnoto-biological 
stand point. 
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In the GR, C3Hf, BALB/c and BALB/cfC3H strain, mammary 
tumours were induced by forced breeding. The mice received 
water and food (AM 2 , Hope Farms, Woerden, The Nether-
lands) ad libitvJ!l. 
Immunized mice were obtained by intraperitoneal (ip) 
injection with 1 ~g MTV precipitated on alum (preparation: 
see 2.9). Male mice not older than 10 weeks served as nor-
mal control animals. Serum was collected from the retra-
orbital plexus under ether anaesthesia; for the experiments 
on cellular immunity, the animals were killed by cervical 
dislocation. 
For the study of the influence of histoincompatibility 
in the leukocyte adherence inhibition (LAI) assay, 7-year-
old male chimpanzees that had been in our colony (Primate 
Center TNO, Rijswijk) for four years were used. 
2.2. Virus purification 
The standard strain of the MTV (Teramoto et al., 1974) was 
isolated from primary BALB/cfC3H mammary tumours in the 
following way: Fifty g of tumour was homogenized in 500 ml 
phosphate buffered saline (PBS) (pH 7.2) in a Sorvall 
omnirnixer (Ivan Sorvall Inc., Norwalk, Conn.) for 50 sec at 
14,000 rpm. The homogenate was centrifuged for 15 min at 
20,000 x g (Sorvall RC2-B, GSA rotor, 12,500 rpm). This 
centrifugation was repeated with the resuspended pellet. To 
the combined supernatants EDTA was added to a final con-
centration of 1 roM. After centrifugation for 45 min at 
100,000 x g (Beckman 35 N rotor, 35,000 rpm; Beckman In-
strument, Inc., Fullerton, Calif.), the pellet was resus-
pended in 1.5 mM Tris HCl (pH 7.2) and 0.025 M sucrose. A 
total volume of 30 ml virus suspension was centrifuged for 
20 min at 20,000 x g (Sorvall RC2-B, SS34 rotor, 12,500 
rpm). This centrifugation step was repeated with there-
suspended pellet. 
Hereafter 15 ml of the combined supernatants was 
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layered on a discontinuous sucrose gradient composed of 4 
ml 50 % sucrose, 12 rnl 3S % sucrose, and 6 ml 20 % sucrose 
(wt/wt) in 1.5 mM Tris-HC1 (pH 7.2). After centrifugation 
for 180 min at 100,000 x g (Beckman SW27.1 rotor, 27,000 
rpm), a sharp light-scattering band on the SO% layer was 
separated, diluted, and layered on a preformed linear 
sucrose gradient (20-SO %) and centrifuged for 180 min at 
100,000 x g. The sharp visible band at a density of 1.16-
1.18 g/cm3 containing the virus was collected, diluted, 
and centrifuged for 45 min at 4S,OOO xg (Beckman SO Ti-
rotor, 40,000 rpm). The virus pellet was resuspended in l.S 
mM Tris-HCl (pH 7.2) in 0.02S M sucrose and stored at-
70° C until use. All isolation steps were performed at 
4° C. The yield was approximately 1 mg virus protein per 
10 rnl of tumour. The polyacrylamide gel electrophoresis 
(PAGE) analysis of virus isolated in this way showed the 
same protein pattern as virus derived from cells grown in 
tissue culture (Westenbrink et al., 1977). RLV was isolated 
from leukaemic spleens of BALB/c mice in the same manner. 
Virus content was estimated on the basis of the amount of 
protein, as measured by the Lowry method. 
2.3. The direct leukocyte adherence inhibition (LAI) assay 
The direct LA! assay for demonstrating immunologic cellular 
reactivity to certain antigens was developed by Halliday 
and Miller (1972). They observed that the proportion of 
cells adhering to glass surfaces was reduced if antigen to 
which the animals were sensitized was added. In this test 
system, the blocking and enhancing properties of serum 
could also be established. Later, it was reported that the 
LA! assay may be regarded as a dependable in vitro test for 
determining immunologic reactivity to tumour specific 
antigens in the case of melanoma (Halliday et al., 1975) 
and breast cancer (Grosser and Thompson, 197S). For these 
reasons, we decided to use the direct LA! assay to monitor 
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MTV-directed cellular immunity in mice bearing mammary 
tumours. 
The assay was performed in the following manner: 
Immediately after killing the mice were injected intraperi-
toneally (ip) by means of a Pasteur pipette with 5 ml of 
ice-cold medium (RPM! 1640 with 100 IU penicillin and 100 
~g streptomycin/ml and 5 x 10-5 M 2-mercaptoethanol) to 
which heparin (5 IU/ml) was added. The fluid was withdrawn 
and re-injected several times and then collected into 
glass tubes. The cells were centrifuged once at 200 x g for 
10 min. Washing was restricted since we noticed that peri-
toneal cells become unresponsive in the direct LAI-assay 
after repeated washing. Cells of immunized DBA£ mice showed 
a significant reduction of adherence of about 30 % upon 
incubation with MTV after one washing. The activity de-
creased to zero after the cells had been washed four times. 
The cells were then resuspended in medium containing 7% 
foetal calf serum (Flow, Irvin, Scotland). The final cell 
concentration was adjusted to approximately 40 x 103/ml. 
Then antigen wa~ added and 20 ~1 of the suspension were 
pipetted into the wells of Falcon rnicrotest 3034 plates. 
The wells for the control and test cells were alter-
nating. This was done because it was sometimes observed 
that more cells adhered in the wells at the edges of the 
plates than in the middle. The amount of cells that adhered 
in the plates was also very low. The plating efficiency 
could be increased by incubation of the plates in PBS for 
two days. Greiner microtest plates (NUrtingen, Germany) 
showed these disadvantages to a lesser extent. Different 
batches of plates may be the cause that the plating 
efficiency in different experiments sometimes varies 
considerably. 
When the wells were filled, the plates were incubated 
in a humidified atmosphere with 5 % co2 for 2 h at 37° 
C. Thereafter, the plates were washed three times in PBS 
and the adherent cells were fixed, stained and counted. 
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At least eight wells for each antigen were counted. To 
avoid non-specific reactions of the indicator cells, puri-
fied RLV was used as a specificity control throughout. Re-
activity was expressed as per cent reduction of adherence, 
which was calculated according to the formula 
a (1 - b) x 100 % in which a is the average number of cells 
adhering in the presence of MTV, and b those adhering in 
the presence of RLV. Statistical significance was estab-
lished by means of the two-tailed Students' t-test. 
For our MTV-S antigen preparation, isolated from BALB/cfC3H 
mammary tumours, the optimal antigen concentration was 0.1 
pg MTV/ml. This is illustrated on fig. 2. For a batch RIII 
virus, isolated from milk (obtained through the Office of 
Resources and Logistics, Virus Cancer Program, National 
Cancer Institute), it was however observed that the optimal 
antigen concentration was 0.01 ~g MTV/ml. This may be due 
to the fact that the antigen concentration is based on the 
80 ~ 60 0 0 
0 , 
" 
40 
0 
. 
. 
0 
20 
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Figure 2: 
Optimal concentration of MTV in the direct LAI-assay 
MTV-specific leukocyte adherence inhibition of peritoneal cells derived 
from immunized C57BL mice in the presence of varying concentrations of 
MTV, as compared to the RLV control value. This figure represents the 
results of one of three experiments. The results from all three experi-
ments were similar. 
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Table 2 
DIRECT LEUKOCYTE ADHERENCE INHIBITION IN NORMAL MALE MICE 
Incubation with 
medium 
Incubation with 
RLV 
Incubation with 
MTV 
Mouse strain Average no. of adherent cells + SE* 
BALB/c 29.2 + 1.6 
BALB/ cfC3H 60.8 + 4.1 
GR 25.6 + 4.2 
* SE: standard error 
** NS: not significant 
28.6 + 3.2 30.0 + 3.5 
43.7 + 3.5 42.3 + 2.3 
19.6 + 2.8 20.3 + 1.8 
Significance of 
difference be-
tween RL V and 
medium control 
NS~'<* 
p < 0.001 
NS 
Significance of 
difference be-
tween RL V and 
MTV 
NS 
NS 
NS 
amount of protein. Also different amounts of group-specific 
antigens in varying MTV-variants may play a role. Therefore, 
for every batch of MTV the optimal antigen concentration was 
again established. 
When pooled cells derived from 3 normal animals were 
tested, a significant difference was sometimes found 
between the number of adherent cells in cultures incubated 
with 0.1 ~g RLV and those to which no antigen was added. 
However, no appreciable differences were found between 
cultures incubated with RLV and MTV. For the strains 
BALB/c, BALB/cfC3H and GR, this is illustrated in Table 2. 
Normal C57BL and DBA mice and BALB/c mice sensitized to a 
plasmacytoma also do not respond to MTV. Neither was a 
significant difference ever found when normal cells were 
incubated with 0.1 pg RLV, as compared to the same amount 
of ovalbumin. C57BL and DBA£ mice immunized with RLV were 
positive to RLV and negative to MTV. 
2.4. The indirect LAI-assay 
Holt et al. (1975) reported that the LAI reaction can be 
abolished by pretreatment of the cells with anti-theta 
serum and complement. He also observed that the inhibition 
of adherence can be transferred to cells from nonimrnunized 
animals by the supernatant of spleen cells incubated with 
the antigen. Therefore, he concluded that a soluble factor, 
the T cell-dependent leukocyte adherence inhibition factor 
(LAIF) is responsible for the inhibition of adherence. We 
developed the indirect LA! assay, in which LAIF, produced by 
spleen cells upon incubation with MTV is transferred to 
normal indicator cells. 
This test was performed under sterile conditions. 
Spleen cells were taken aseptically and teased apart by 
forceps in a petri dish containing medium. The debris was 
then allowed to settle in a tube. The supernatant contain-
ing the cells was centrifuged twice at 26 x g for 10 min to 
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FigUI'e 3: 
Optimal spleen cell concentration per ml in the indirect LAI-assay 
MTV-specific LAIF production at varying spleen cell concentrations. 
Pooled spleen cells from five immunized DBA£ mice were used. Incubation 
time of the cultures was 24 h. Vertical bars indicate SE of the per-
cent reduction of adherence. Shown in the figure are the results of one 
out of three experiments. The results from the three experiments were 
similar. 
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Figure 4: 
Optimal- incubation time of cultures in the indirect LAI~-assay 
MTV-specific LAIF production by pooled spleen cells derived from five 
immunized DBA£ mice in the presence of 1 pg MTV, after varying incu-
bation times. Vertical bars indicate SE of the per cent reduction of 
adherence. This experiment has been repeated with similar results. 
32 
remove erythrocytes and afterwards centrifuged twice at 200 
x g for 10 min. This was done to remove LAIF that could 
have been produced by the cells in vivo through stimulation 
by the expression of MTV-antigens in the animal. 
After counting, the spleen cells were resuspended in 
medium supplemented with 10 % foetal calf serum. The 
cultures (1 ml) were incubated in plastic tubes (Falcon, 12 
x 75 mm) for 24 h with 0.1 ~g antigen in a humidified 
atmosphere with 5 % co 2 . The cells were subsequently spun 
down and the supernatant was removed. 
As indicator cells fresh peritoneal cells derived from 
normal animals were used. The cells were washed 4 times at 
200 x g for 10 min. 
The indicator cells were then suspended in the super-
natant of the spleen cells to a final concentration of ap-
proximately 40 x 10 3 cells/ml, and 20 ~1 was again 
pipetted into the wells of microtest plates. The plates 
were then treated as described for the direct LA! test; 
percentage reduction of adherence was also calculated in 
the same way. In this assay the optimal antigen concentra-
tion for MTV-S derived from BALB/cfC3H mammary tumours was 
again 0.1 ~g. 
Optimal conditions for the indirect LA! assay. In the 
indirect test, the highest response was obtained if the 
spleen cell concentration was 20 x 106/ml (Figure 3). On 
prolonging the incubation time of the spleen cells, LAIF 
production also increases. A maximum is reached after 24 h 
(Figure 4). 
We compared the reactivity measured with the direct and 
the indirect method of pooled cells from immunuzed DBA£ 
mice. The indirect assay was performed using the optimal 
spleen cell concentration (20 x 10 6;ml) and incubation 
time (24 h). The results are shown in table 3. Reactivity 
is higher when the indirect method is used. From the 
results it is clear that the SE values of both assays are 
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Table 3 
COMPARISON OF REDUCTION OF ADHERENCE OF CELLS FROM THE SAME IMMUNIZED ANIMALS AS MEASURED BY THE DIRECT AND 
THE INDIRECT LAI ASSAY 
Exp. no. 
2 
3 
4 
5 
Incubation 
with RLV 
Direct LAI-assay 
Incubation 
with MTV 
Average no. of adherent 
cells + SE** 
23.6 + 2.8 21.0 + 1.3 
25.4 + 1.2 22.0 + 0.4 
54.3+5.7 38.6 + 0.8 
28.2 + 0. 7 21.9 + 1.9 
78.3 + 3.4 65.8 + 2.1 
* statistically significant (p < 0.010) 
** SE: standard error 
Reduction of 
adherence (%) 
11 
13 
29* 
23* 
16* 
Incubation 
with RLV 
Indirect LAI-assay 
Incubation 
with MTV 
Average no. of adherent 
cells + SE 
65.3 + 0.9 40.5 + 2.3 
64.5 + 3.2 43.2 + 2.5 
16.3 + 1.5 8.5 + 2.1 
75.8 + 3.8 34.1 + 0.6 
91.8 + 5.2 58.6 + 2.8 
Reduction of 
adherence (%) 
38* 
33* 
48* 
55* 
37* 
similar. Also, on several occasions we tested the repro-
ducibility of both assays; in both tests the results did 
not deviate from each other by more than 5 % (results not 
shown). For these reasons, it is concluded that the 
indirect assay is more sensitive than the direct test. 
When the direct and indirect LA! tests, both performed 
with peritoneal cells, are compared at an incubation period 
of 2 h, a similar reactivity is found in both tests. In the 
indirect LA! assay spleen cells gave better results than 
peritoneal cells. This is illustrated in table 4. LAIF-
production by spleen cells may be higher because the 
proportion of T cells is higher in spleen cells than in 
peritoneal cells. It could be anticipated that also in the 
direct assay spleen cells will probably give better 
results. However, this could not be tested: When spleen 
cells were used as indicator cells it was noticed that 
standard deviations became larger, probably due to 
overcrowding of the wells by non-adhering cells. 
The greater sensitivity of the indirect assay as corn-
pared to the direct test is also due to the longer incu-
bation period used. It is impossible to use such long 
incubation times in the direct assay, since the standard 
deviations of the results increase greatly with prolong-
ing the incubation time. In addition, the role of spleen 
cell subpopulations and lymphokines can be investigated 
more conveniently by means of the indirect LAI-assay. 
For these reasons, the indirect assay was preferred 
over the direct assay in later studies (Chapters IV and 
V). 
Influence of histoincompatibility. An interesting 
question was whether LAIF can be transferred to the adherent 
cells from mice of other strains or cells from a distantly 
related species. For this reason, it was investigated 
whether LAIF derived from spleen cells of immunized DBA£ 
mice could be transferred to the adherent cells of BALB/c 
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Table 4 
MTV-SPECIFIC LAIF PRODUCTION BY IMMUNE CELLS AS MEASURED BY THE DIRECT AND THE 
INDIRECT LAI ASSAY DURING A 2 H INCUBATION PERIOD 
Method and 
cell population 
Direct LA! 
Peritoneal cells 
Indirect LAI 
Peritoneal cells 
Spleen cells 
Experiment 1 
Incubation Incubation 
with RLV with MTV 
Average no. of adherent 
cells + SE* 
14.8 + 0.5 10.8 .:': 0.9 
29.3 + 1.3 21.0 + 0.9 
15.8 + 0.6 10.0 + 1.0 
*sE: standard error 
Exp. l Exp. 2 Exp. 3 
Reduction of adherence 
{%)** 
27 20 15 
28 18 19 
37 31 27 
** all values for per cent reduction of adherence are significant {p < 0.010) 
and C57BL mice and to those of chimpanzees. For the testing 
of the chimpanzees, lymphoid cells from pooled peripheral 
blood of three animals were purified by Ficoll-Hypaque 
sedimentation and washed 4 times in medium. They were then 
suspended in the supernatant to a final concentration of 
106 cells/ ml~ 20 pl were used/well. The MTV-specific LAIF 
production by the DEAf-derived immune spleen cells as 
measured when lymphoid cells from other mouse strains and 
the chimpanzees are used as indicator cells is shown on 
Table 5. 
From these results, it is clear that histoincompatibi-
lity within the same species does not interfere in this 
test. Thus, when only small numbers of a certain mouse 
strain to be tested were available, indicator cells were 
derived from another mouse strain. The murine LAIF cannot 
be transferred to another species. 
Testing for blocking or enhancing capacities of serum. 
To determine the influence of serum on the indirect LAI 
reactivity, 0.1 ml of serum to be tested was added to 0.9 
rnl cultures of immune spleen cells and 0.1 pg of MTV; 0.1 
ml of syngeneic mouse serum served as a control. Blocking 
or enhancing capacity of serum was expressed by the 
formula: quotient y = TS/NS, in which TS is the number of 
adherent cells in the wells containing test serum and NS 
that in the wells containing normal serum. Since no speci-
ficity control was included, the blocking or enhancing 
properties of the sera that is measured may be partly 
aspecific. 
2.5. Leukocyte stimulation (LS) test 
This test, known as mitogen stimulation is in common use 
for measuring non-specific immune competence with plant 
lectins. Incorporation of 14c-thymidine is then taken as 
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Table 5 
MTV-SPECIFIC LAIF PRODUCTION BY DEAf-DERIVED IMMUNE SPLEEN CELLS MEASURED WITH PERITONEAL CELLS 
FROM OTHER MOUSE STRAINS, AND WITH LYMPHOID CELLS OF CHIMPANZEES AS INDICATOR CELLS 
Exp. 1 Exp. 1 Exp. 2 Exp. 3 
--- ---
--
Origin of Incubation Incubation 
indicator cells with RLV with MTV 
Average no, of adherent Reduction of adherence 
cells + SE'~ (%)** 
A DBA£ mice 79.5 + 2.3 63.5 + 1.5 20 24 17 
BALE/ c mice 30.4 + 1.1 25.1 + 1.2 17 21 20 
C57EL mice 50.2 + 2.6 40.1 + 1.3 20 19 15 
B DEAf mice 34.3 + 1.6 11.8 + 2.0 66 28 43 
chimpanzees 96.0 + 2. 7 96.7 + 4.2 0 4 3 
SE: standard error 
all values, except those of cells from chimpanzees, are significant (p < 0.010). 
a measure for cell proliferation. The LS test can also be 
used to measure a specific immune response. Spleen cell 
preparations were obtained as described above. When lymph 
node cells were tested, they were teased apart by forceps 
in a petri dish containing medium and spun 4 times at 200 g 
for 10 min. After counting, the cells were resuspended (2.5 
x 10 6 /ml} in medium supplemented with 20 % FCS. The 
cultures (1 ml) were incubated for 80 h in plastic tubes 
(75 x 12 mm, Falcon} in the presence of antigen at 37° C 
in a humidified atmosphere with 5 % co 2 . After this, 0.15 
~Ci of 2-14c-thymidine was added to each culture. Twenty-
four h later, the cells were collected by suction onto 
glass fibre filters (Whatrnan GF/A, Maidstone, England) and 
washed two times; incorporation of 14c-thymidine was 
measured in a liquid scintillation counter. 
The cultures were run in triplicate. Percentage of 
stimulation was calculated according to the formula a - b/b 
x 100 %, in which a = average number of counts/min (cpm} in 
cultures incubated with MTV and b that in cultures incuba-
ted with RLV. Statistical significance was established by 
means of the two-tailed Students't-test. 
With lymphoid cells from immunized mice, the optimal 
conditions for stimulation, as measured by 14c-thymidine 
uptake, are 80 h of incubation (Figure 5) and 0.1 pg viral 
protein when MTV-S, isolated from BALB/cfC3H mammary 
tumours was used (Figure 6). Also in this testis was neces-
sary to establish the optimal concentration of antigen for 
each new batch of antigen. 
From repeated experiments (3 for every mouse strain), 
it became clear that spleen cells from normal animals 
sometimes show an enhanced response with RLV as compared to 
the medium control experiment. This is demonstrated in 
Table 6. In this case also, the same values are found for 
RLV and MTV. This also holds true for RLV as compared to 
ovalbumin. Therefore, in this test RLV is again taken as 
the specificity control. 
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Table 6 
14c-THYMIDINE INCORPORATION OF SPLEEN- AND LYMPH-NODE CELLS OF NORMAL MALE MICE 
Mouse strain 
BALB/c 
GR 
BALB/cfC3H 
Incubation with 
medium 
cpm + SE 
2.010 + 298 
2.078 + 266 
3.619 + 72 
* SE: standard error 
** NS: not significant 
Incubation with 
RLV 
cpm ~ SE 
1. 992 + 146 
3.862 + 308 
7.912 + 518 
Incubation with 
MTV 
cpm + SE 
1.708 + 312 
3.366 + 352 
7,334 + 405 
Significance of 
difference between 
RLV and medium 
control 
NS** 
p < 0.025 
p < 0.001 
Significance of 
difference between 
RLV and MTV 
NS 
NS 
NS 
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Figure 5: 
Optima~ incubation time of cuLtures in the LS-assay 
14
c-thymidine incorporation of pooled spleen cells from three immunized 
BALB/c mice after varying incubation times, in the presence of 1 ug 
MTV. The RLV control value was 5.3 x lo-3 cpm. Vertical bars indicate 
SE of triplicate cultures. Shown in the figure are the results of one 
out of four experiments. The results of all experiments were similar. 
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Optimal MTV-concentration in the LS assay 
14
c-thymidine incorporation of pooled spleen cells from three immunized 
BALB/c mice in the presence of varying concentrations of MTV. Incuba-
tion time was 80 h. The RLV control value was 4.8 x lo-3 cpm. Vertical 
bars indicate SE of triplicate cultures. Shown in the figure are the 
results of one out of three experiments. The results of the three ex-
periments were similar. 
41 
Testing for blocking and enhancing properties of serum. 
The influence of serum was established by adding 0.1 ml 
test serum to the cultures; normal serum served as a 
control. MTV was added to both test and control cultures. 
Inhibition by serum factors was expressed as a percentage 
of the values of normal serum according to the formula 
(1 -TS/NS) x 100 % in which TS is the average cpm of the 
cultures containing test serum, and NS represents that of 
the cultures containing normal serum. Also per cent inhi-
biotion by other suppressive agents (Chapter V) was cal-
culated in this way. 
2.6. Separation uad testing of spleen cell subpopulations 
Macrophages were removed by adherence of spleen cells (4 x 
106/ml) to the surface of Falcon tissue culture flasks 
{25 cm 2 ) during 2 - 3 h, or with the iron-magnet method. 
B cell-enriched fractions were obtained by incubating 
macrophage-depleted spleen cells with mouse anti-theta 
serum and complement for 1 h. The anti-theta serum was made 
by injecting 2 x 107 thymocytes derived from C3H mice ip 
into AKR mice. This was done six times at intervals of 14 
days. Then the AKR mice were bled; the resulting anti-theta 
serum killed 70 % of C3H thymocytes up to a dilution of 
1/16. As a source of complement, guinea pig serum absorbed 
with agarose and stored in liquid nitrogen was used. The 
complement was active up to a dilution of 1/8. After 
treatment the cells were washed and used for testing. 
T cell-enriched populations from spleens were obtained 
by passage over a nylon wool column (Julius et al., 1973). 
After washing with medium about 20 % of the original cell 
population was recovered. Sixty - 88 % of the eluted cell 
population could be killed with mouse anti-theta serum and 
complement, whereas 3 - 10 % were Ig-positive in membrane-
immunofluorescence studies (tested 6 times). 
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2. ?. Detection of MI'V and mouse anti-MTV antibodies 
Membrane immunofluorescence. This method was mostly 
used to detect mouse anti-MTV-antibodies. Unless mentioned 
otherwise, the MTV positive AR 963 cell line that was 
developed from a C3H mammary tumour (Van Pelt, et al., 
1976) was used as a target cell. After trypsinization, the 
cells were dispersed in Falcon Micro Titer 3034 plates with 
a Hamilton syringe (Sorg, 1974) (Hamilton Co., Whittier, 
Calif.). After a 45 min incubation with the test serum, the 
plates were washed three times in medium. Thereafter, they 
were incubated for 30 min with goat antiserum directed 
against mouse Ig, conjugated with fluorescein isothiocya-
nate (FITC) (Nordic Immunodiagnostics, Tilburg, The 
Netherlands) in a dilution of 1 : 20 in PBS. After three 
washings in medium, the cells were examined with an 
inverted Leitz Biovert microscope (E. Leitz, Inc., New 
York, N.Y.) equipped for epi-illumination with the fol-
lowing filter combinations: excitation, 2 x KP 490 + 1 mrn 
Gg 455t emission, K 515 + KP 560. A 50 x /1.0 water-
immersion objective and 6.3 x oculars were used. The sera 
were tested in two log dilutions. All sera were tested two 
times. Cells incubated with normal mouse serum and goat 
anti-mouse IgG-FITC, and cells incubated with PBS and the 
conjugate served as negative controls. Cells, incubated 
with positive mouse serum, and cells incubated with goat 
anti-MTV serum and subsequently with goat anti-goat IgG-
FITC served as positive controls. 
Lymphoid cells that were tested for the presence of Ig, 
theta-antigen, anti-MTV antibodies or MTV on the cell mem-
brane were, except for the use of different antisera, 
treated in the same way. 
Sepharose bead immunofluorescence assay. The method 
developed for the assay of immunoglobulins (Haaijman and 
Brinkhof, 1977) has been adapted to the detection of MTV 
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+ • 
MTV 
Sepharose-RoM TV-5 
+ v- FITC FITC 
RaMTV-5-FITC 
B 
mouse onti-MTV 
Sep her ose- vi ro 1-pr ole ins 
+ D- FITC 
gaol onti-mouse/lg-FITC FITC 
Figu:t>e ? : 
Detection of MTV and crt~ti-MTV antibodies by the Sephax>ose-bead irnrrn.;.no-
fluorescence assay. 
A: Detection of MTV. Rabbit anti-MTV-S serum (RaMTV-S) is coupled to 
Sepharose beads. After incubation with the sample to be tested, MTV is 
attached to the rabbit anti-MTV-S serum. MTV is then detected by in-
cubation with rabbit anti-MTV-S IgG coupled to FITC (RaMTV-S-FITC). 
B: Detection of mouse anti-MTV antibodies. MTV is coupled to Sepharose 
beads. After incubation with the serum to be tested, mouse anti-MTV 
antibodies are attached to MTV; the mouse anti-MTV antibodies are then 
detected by incubation with goat anti-mouse Ig coupled to FITC. 
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antigens (Haaijman, 1977). A rabbit antiserum to MTV was 
subjected to chromatography on QAE-Sephadex A50 (Pharmacia, 
Uppsala, Sweden) in ethanol-diamineacetate (pH 8.0; I 0.1), 
according to Joustra and Lundgren (1969). The isolated IgG 
fraction was dialyzed against PBS. To obtain a specific 
anti-MTV fraction, the IgG was then passed over an immune-
adsorbent column, prepared according to Radl et al. {1974) 
consisting of immobilized normal mouse serum and an MTV-
negative BALB/c mammary gland extract. Part of the unbound 
IgG was then coupled covalently to Sepharose 4-B beads 
(Pharmacia) by the cyanogen bromide method of March et al. 
{1974), using 2 mg protein per ml of activated beads. Resi-
dual active groups were deactivated by treatment of the 
beads for 6 h with 0.5 M ethanolamine, pH 9.5. The beads 
were then washed and stored in PBS with 0.01 % merthiolate. 
Another part of the IgG fraction was conjugated with FITC 
according to Hijmans et al. (1969). 
For the determination of viral antigens, 50 pl of a 
suspension of anti-MTV beads was incubated for 1 h with 50 
~1 of a cell-free sample diluted in PBS containing 2 % 
bovine haemoglobin, in microtitration plates with continu-
ous agitation. Control beads were incubated with PBS. After 
repeated washing, the beads were incubated with the FITC-
conjugated antiserum to MTV (figure 7A). 
After repeated washing the individual bead fluorescence 
was measured with a microfluorometer. At least five beads 
were measured per dilution. 
For the detection of antiviral antibodies, beads 
coupled with MTV were used. Disrupted MTV was passed over a 
column consisting of a goat antiserum to normal mouse 
serum, coupled to Sepharose 48 as described above. There-
after, the MTV preparation from which most host components 
were removed, was coupled to Sepharose beads as described 
above. 
The beads were then incubated for 1 h with the samples, 
and then after repeated washing incubated with a goat anti-
serum directed against mouse immunoglobulins (figure 7B). 
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Beads coupled with normal BALB/c mouse serum served as a 
control. 
2.8. Vaccination experiments 
Preparation of vaccine. After ultrasonic disruption of 
the MTV-virions, host proteins, which constituted approxi-
mately 20 % of the total protein content of the virus 
preparation, were removed by absorption with Sepharose 4B 
beads covalently coupled with MTV-negative goat antimouse 
mammary gland serum. This virus protein fraction was 
chromatographed over a Con A-Sepharose 4B column. Bound 
glycoproteins were eluted with 0.2 M methyl-a-D-mannopyra-
noside in PBS. The eluted proteins were thereafter dialyzed 
against PBS {pH 7.2) for 4 days. The proteins in the 
fraction were identified by 0.1 % SDS {pH 7.0) - PAGE 
{Weber and Osborn, 1969). The gels were scanned spectra-
photometrically in a gel scanner at 540 nm {Figure 8). In 
the preparation are a number of contaminants derived from 
Con A. They have the following molecular weights: 75,000; 
28,000; 18,000; and 14,000 D. This has been estimated by 
PAGE with the use of various reference molecules. The major 
part {60 %) of this protein preparation was gp52. The vac-
cines of disrupted virus used in the experiments were ob-
tained by freeze-thawing ten times. 
When no adjuvant was used, the gp52-enriched protein 
fraction was diluted in PBS for the vaccination. When virus 
or the gp52-enriched protein fraction was precipitated on 
alum, the proteins were dissolved in 0.25 ml PBS; after the 
addition of 0.11 ml 1 N bicarbonate solution, 0.25 ml of a 
10 % alum solution was added. The solution was left 
overnight at 4° C, and the alum precipitate was then 
pelleted by centrifugation at 3,000 rpm for 30 min. No 
proteins could be detected in the supernatant. The precipi-
tate was afterwards dissolved in PBS to the desired concen-
tration. 
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Figure 8: 
Identification of poLypeptides in the ~~V-S protein vaccine 
SDS 0.1 % (pH 7.0) - 10% polyacrylamide gel electrophoretic analysis 
of the HTV-S polypeptide fraction eluted from a Con A-Sepharose 4B 
column. The protein fraction was dissociated at 1000 C for 2 min in the 
presence of 1 % SDS and 1 % ~ -mercapto-ethanol. Electrophoresis was 
done for 18 h at 3 rnA/gel. The gel was stained with Coomassie blue and 
scanned at 540 nm. 
When virus or the gp52-enriched protein fraction was 
used in combination with !PM, both proteins were dissolved 
in PBS. The !PM was provided by Dr. Lamensans, Institute 
Pasteur, Paris, France. 
Challenge with tumour cells. For the study of trans-
plantation resistance 1 vaccinated mice were challenged with 
their syngeneic tumour: BALB/c mice were injected with an 
MTV-0 induced tumour, GR mice with an MTV-P induced tumour 
and the DBA£ mice with the Ll210 leukaemia. Before chal-
lenge, the solid mammary tumours were forced through a fine 
steel mesh; after washing (3 times 26 x g for 10 min) in 
medium, the cells were drawn through a fine-gauge needle. 
The viable cells were then counted and injected subcutane-
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ously (sc) into the mice. 
The Ll210 leukaemia was maintained alternately in vivo 
and in vitro for periods of 2 weeks. The cells were main-
tained in vitro in plastic Falcon culture flasks (Flow 
Laboratories, Irvine, Scotland) and in vivo by ip injection 
into (DBA£ x BALB/c)Fl mice. Before challenge, the cells 
were washed once and drawn through a fine gauge needle; 
afterwards, they were injected ip into the mice. 
The challenge dose varied (see Chapter VI). 
Experimental design. To test transplantation resistance 
in BALB/c and DBA£ mice, different doses of vaccines were 
injected ip into the animals. Controls were treated with 
the adjuvant alone. Controls and vaccinated animals were 
challenged simultaneously with tumour cells 20 days after 
vaccination. To investigate the influence of the adjuvants, 
a group of untreated animals was challenged with tumour 
cells. After challenge with a mammary tumour, the animals 
were examined every 3 days; they were killed as soon as a 
tumour was observed. The experiments were terminated 30 
weeks after challenge; animals that had developed no tumour 
by then were considered as survivors. When the animals were 
challenged with leukaemia cells, death was taken as a para-
meter for tumour incidence. Deaths were recorded two times 
a day; if the animals had not died at 5 weeks after chal-
lenge, they were scored as survivors. Statistical differ-
ences of latency periods between vaccinated and control 
animals were established by the two-tailed Students't-
test. 
At several intervals after vaccination, 2 animals from 
each group were bled from the retro-orbital plexus and, 
after killing by cervical dislocation, the combined perito-
neal cells were taken for the in vitro studies on immunity. 
The sera were also pooled. 
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In the experiments on vaccination against primary tumour 
development, female mice were inoculated s.c. with the vac-
cine at 8 - 16 weeks of age; at the age of 22 - 37 weeks, 
they were subjected to forced breeding. The mice were exa-
mined twice a week for the presence of tumours. They were 
killed immediately when such signs were present. Animals, 
that did not develop a mammary tumour were permitted to 
live out their lifespan. 
Cellular immune reactivity was, besides- by means of the 
direct LA! assay, also investigated with the Winn-assay. 
For this test, five thousand syngeneic mammary tumour cells 
suspended in RPM! 1640 medium were mixed with 5 or 25 x 
10 6 immune spleen cells and injected sc into syngeneic 
6-week-old mice. Control animals were injected with the 
same mixture of normal spleen cells and tumour cells {Winn, 
1961). The grafted mice were examined every three days for 
tumour development. The observation period w~s five 
months. 
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CHAPTER III 
MTV-DIRECTED IMMUNITY IN MICE DURING THE GROWTH OF 
SPONTANEOUS TUMOURS 
Although healthy mice show immunologic responses 
against the antigens of MTV-induced tumours, this response 
is unable to prevent tumour development. After development 
of a mammary tumour the anti-MTV responses become even 
higher (Chapter I: 3,4). It may therefore be concluded that 
MTV antigens are immunogenic. Nevertheless, this immune 
response is inadequate. Just before the tumour becomes 
clinically detectable, antigen levels in the blood of mice 
increase sharply (Ritzi et al., 1976). The possibility 
exists that antigen in the circulation inhibits the immune 
effector arm. 
Since it is a very complicated procedure to study mice 
that are just about to develop a tumour, we decided to 
investigate mainly the anti-MTV responses in mice bearing 
spontaneous mammary tumours of varying sizes. We investi-
gated animals of the GR, the BALB/c and the BALB/cfC3H 
strain; tumour development in these mice was stimulated by 
forced breeding. The presence of anti-MTV antibodies in 
sera from individual tumour bearing mice was established by 
membrane immunofluorescence on living tumour cells. Cellu-
lar immunity was investigated with both the direct LA! and 
the LS assays. Individual mice were tested with the LA! 
assay; LS tests were performed with pooled cells from three 
mice bearing tumours of approximately the same size. MTV-S 
was used as an antigen in both tests. 
3.1. Membrane immunofluorescence 
The presence of anti-MTV antibodies was established by 
means of membrane immunofluorescence. We tested undiluted 
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Table 7 
MTV-ASSOCIATED* MEMBRANE IMMUNOFLUORESCENCE WITH SERA FROM TUMOUR 
BEARING BALB/c MICE 
serum donors 
Mouse strain MTV-strain tumour weight 
(g) 
BALB/c MTV-0 2.0 
3.2 
4.0 
BALB/cfC3H MTV-S 0. 7 
1.3 
1.8 
2.3 
5.0 
fluorescence on 
of cultures 
G--MTC** 
45 min 16 h 
- + 
- + 
- + 
+ + 
++ ++ 
++ ++ 
* All sera revealed negative results when tested on BALB/c derived 
embryonic fibroblasts. 
** GR-MTC: GR-derived mammary tumour cells 
mouse sera, since dilution rapidly led to the disappearance 
of positive fluorescence. In addition to the commonly used 
serum incubation time of 3/4 h, we also tested fluorescence 
after an incubation period of 16 h. Since the anti-MTV 
antibodies in mice that are induced by different MTV vari-
ants also react to the group-specific antigens of MTV (Ihle 
et al., 1976), the sera from the BALB/c strains were tested 
against GR-derived mammary tumour cells. BALB/c-derived em-
bryonic fibroblasts served as a specificity control. 
The results are summarized in table 7. From these re-
sults it is obvious that tumour bearing BALB/c and BALB/cf 
C3H mice have antibodies in their serum which give a broad 
cross-reactive membrane fluorescence with GR mammary tumour 
cells producing MTV-P. Mice which were infected with MTV-S 
along with the endogenous MTV-0 showed a much stronger re-
action than mice infected with MTV-0 only: the latter sera 
gave positive results only after the prolonged incubation 
period of 16 h. Absorption of one positive BALB/c and one 
positive BALB/cfC3H serum with purified MTV-S led to abro-
gation of most, but not all fluoresence. When the sera were 
incubated for 3/4 or 16 h on BALB/c embryonic fibroblasts, 
no fluorescence was observed. These results indicate that 
the antibody concentration varies between animals carrying 
tumours of different sizes. 
To investigate if there is any relation between anti-
body level and tumour growth, we tested the sera from three 
individual tumour bearing GR mice over a period of 3 months 
at intervals of two weeks. The bleeding was started when no 
tumour could be detected. Twice a week the animals were 
searched for tumours. The sera obtained from the last 
bleeding before the tumour became clinically detectable, 
and from all following bleedings were used for the membrane 
immunofluorescence studies. Primary cultures of GR-derived 
mammary tumour cells were used as target cells, GR-derived 
embryonic fibroblasts served as a specificity control. In-
cubation time of sera was 3/4 h. All sera from one animal 
were tested simultaneously. The results are summarized in 
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Table 8 
MEMBRANE IMMUNOFLUORESCENCE WITH SERA TAREN FROM GR MICE IN THE COURSE OF 
TUMOUR DEVELOPMENT 
day of testing 
l** 
l3 
27 
43 
51 
65 
78 
fluorescence on cultures of GR-derived 
mammary tumour cells* 
mouse 1 
+++ 
+++ 
++ 
++ 
mouse 2 
+ 
+ 
++ 
++ 
mouse 3 
NT*** 
+++ 
++ 
+ 
* All sera yielded negative results when tested against GR-derived embryonic 
fibroblasts. 
** day one refers to the date of the last bleeding before the tumour became 
clinically detectable. 
*** NT: not tested. 
table 8. They clearly show that antibody concentration in 
GR mice oscillates during tumour growth; antibodies are 
sometimes even absent. 
3.2. Direct LAI assay 
When peritoneal cells derived from individual BALB/c, 
BALB/cfC3H and GR mice bearing primary tumours were tested 
in the direct LAI-assay, a significant difference in the 
number of adherent cells between the wells with MTV and RLV 
was found in 18 out of 42 animals tested. 
During the experiments with individual mice bearing 
tumours, it was constantly observed that reactivity was 
highest when the tumour was small (varying from 0.5 to 1.7 
g); with increasing tumour weight, reactivity disappeared, 
whereas animals bearing very large tumours (above 3 to 4 g) 
again showed some reactivity. Since differences in the 
agents used may exert some influence on the reactivity 
measured, individual BALB/c, BALB/cfC3H and GR mice bearing 
primary tumours of varying size were tested with the same 
antigen preparation and batch of FCS. The results are shown 
in fig. 9. 
It was found that reactivity was stronger in BALB/cfC3H 
mice than in the other two strains. Therefore it was in-
vestigated whether type-specificity of the MTV strain that 
is used as the antigen influences the results obtained in 
the LAI-assay. Inhibition of adherence of peritoneal cells 
from GR mice after incubation with the autologous HTV 
strain (MTV-S) and with homologous MTV-P was tested. The 
results, summarized on table 9, indicate that MTV-specific 
cellular immune reactivity as measured with the LAI assay 
is not dependent on type-specificity. 
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Table 9 
DIRECT LEUKOCYTE ADHERENCE INHIBITION IN TUMOUR BEARING GR MICE UPON INCUBATION WITH DIFFERENT 
MTV STRAINS 
Incubation with RLV 
Exp. no. 
l 14.4 + 2.1 
2 86.8 + 5.8 
3 27.6 + 1.5 
4 42.0 + 3.2 
* SE: standard error 
Incubation with MTV-S Incubation with MTV-P 
Average no. of adherent cells + SE* 
8.0 + 1.6 
49.2 + 3.4 
25.1 + 1.0 
28.2 + 2.1 
6.5 + 0.9 
45.7 + 3.9 
21.4 + 3.0 
24.1 + 3.2 
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Figure 9: 
MlV-specific LAI-reactivity of peritoneal cells from twnour-bea:t'ing mice 
Individual mice bearing primary tumours of varying size were tested by 
means of the direct LAI-assay. All tests were performed with the same 
MTV-S antigen preparation and the same batch of FCS. 
0: BALB/cfC3H mice; D GR mice; t:. BALB/c mice. 
A dot in the symbols indicates significant (p < 0.025) reduction of 
adherence as compared to the RLV control value. 
3.3. LStest 
In this assay we tested pools of cells derived from mice 
bearing tumours of approximately the same size. The spleen, 
the axillary and the inguinale lymph nodes were removed; 
the isolated cells were pooled prior to testing. Spleen 
cells and lymph node cells were tested separately. 
In 29 out of 62 tests performed with cells from tumour 
bearing animals, a reaction specific for MTV as compared to 
RLV was observed. The 14 c-thymidine uptake was 2 - 4 
times that of the control. 
In this assay, the fluctuation in response also seemed 
to be related to tumour size. In fig. 10 are plotted the 
values for MTV-specific stimulation against tumour weight. 
The data were obtained in a very short period of time {l 
month). To keep conditions as standardized as possible, the 
same antigen preparations and FCS batch were used. A simi-
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Table 10 
14 c-THYMIDINE INCORPORATION OF SPLEEN CELLS FROM TUMOUR BEARING MICE UPON INCUBATION 
WITH DIFFERENT MTV STRAINS 
Mouse strain MTV strain 
BALB/c MTV-0 
GR MTV-P 
* SE: standard error 
Incubation 
with RLV 
3.003 + 938 
2.403 + 273 
l. 751 + 714 
Incubation with 
homologous MTV-S 
cpm ~ SE* 
6.242 + 1.038 
4.881 + 139 
3.743 + 3 24 
Incubation with 
Autologous MTV 
6.276 + 1.234 
5.029 + 460 
3.380 + 138 
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Figure 10: 
MTV-specific 14c-thymidine-incorporation of spleen and lymph node cells 
from ~umour-bearing BALB/cfC3H mice 
The tests were performed with pools of cells derived from three animals 
bearing tumours of approximately the same size. For all tests, the 
same MTV-S antigen preparation and batch of FCS were used. 
D: spleen cells; 0: lymph node cells. 
A dot in the symbols indicates significant (p < 0.025) stimulation as 
compared to the RLV control value. 
lar fluctuation related to tumour size as was found with 
the LA! assay is observed. It is remarkable that the re-
sults for spleen cells do not parallel those obtained with 
lymph node cells. In various other experiments, we noticed 
the same general pattern: peak reactivity when tumour 
weight is small, a steep decline with increasing tumour 
weight and partial recovery when tumour size is very 
large. 
The specific response to MTV is not dependent on the 
virus strain that is used as antigen. A representative 
experiment is shown in table 10; repeated tests yielded 
similar results. 
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3.4. Discussion 
Tumour bearing BALB/c and BALB/cfC3H mice express anti-
bodies against GR tumour cell membranes; since this reac-
tion is partly inhibited by adsorption with MTV-S, anti-MTV 
antibodies are likely to be present. This is in accord with 
previous findings (Bentvelzen eta!., 1970: Ihle et al., 
1976). It was remarkable that some sera showed positive 
fluorescence only after a prolonged incubation period of 16 
h; this might indicate that these sera contained only very 
low concentrations of antibody, or that the antibody was 
bound to antigen and that the resulting complexes had only 
a very weak affinity for the target cells. 
The results with the individual tumour bearing GR'mice 
clearly show that the antibody content fluctuates in this 
strain; the results from the BALB/c mice bearing MTV-0 and 
MTV-S induced tumours indicate that the antibody content in 
this strain during tumour growth is also not stable. Reac-
tivity was stronger in the BALB/cfC3H strain than in BALB/c 
mice; this may be due to the fact that virions of the dif-
ferent MTV strains show some serological differences, as 
detected by heterologous antisera (Daams et al., 1973; 
Teramoto et al., 1977). 
With two different techniques, the LAI and the LS tests, it 
was found that mice bearing mammary tumours have cellular 
immunity to MTV. Specificity of the reaction was mainly 
deduced from significant differences in reactivity of the 
peritoneal cells when relatively small amounts of MTV were 
added as compared to the addition of similar amounts of an 
unrelated oncovirus (RLV) or ovalbumin. 
The stimulation of cell proliferation as measured by 
1 4c-thymidine uptake upon incubation with MTV is relati-
vely low (2-4 times the control value) as compared to 
stimulation by plant lectins. Similar low values have been 
found in the mixed leukocyte-tumour cell interaction test 
for a virally induced rat lymphoma (Glaser et al., 1975). 
60 
It is remarkable that very often when the spleen cells 
of tumour-bearing animals were reactive in the LS-assay, 
the lymph node cells from the same animals did not respond, 
or vice versa. This phenomenon has also been observed in 
the microcytotoxicity test for the Bl6 mouse melanoma 
(Bartholomeus et al., 1974). 
In the LAI and LS tests, the anti-MTV reactivity seems 
to be mainly evoked by group-specific antigens. 
In the present study, the results of LAI and the LS assays 
seem to coincide; it must be mentioned however, that cells 
from the same animals have not been compared in both 
tests. 
In both tests, the highest reactivity was found when 
the animals had small tumours. This indicates that a rela-
tion exists between cellular immunological reactivity and 
antigenic load, although tumour weight is only a rough 
estimate of the latter. From other animal studies (Rowland 
et al., 1972; Blair, 1976; Glaser et al., 1975) it is also 
known that cellular immunological reactivity is generally 
diminished with increasing tumour size. Decreased reacti-
vity against tumour specific antigens, as revealed by re-
duced transplantation resistance (Vaage, 1973), may be as-
sociated with the general immunological impairment. 
After the initial peak in reactivity at low tumour 
weight, an almost complete loss of activity was found; how-
ever, in animals with very large tumours (above 3 g), the 
activity reappeared again, but at a lower level than was 
found with cells from animals with small tumours. Thus, 
cellular reactivity fluctuates. For opsonins, also an 
oscillation during tumour growth has been observed (Saba 
and Antikatzides, 1975). 
An explanation for the decrease in cellular responsiveness 
to MTV in both tests may be the saturation of receptors of 
irnmunocytes with increasing amounts of viral antigens that 
are released into the blood stream when the tumour progres-
ses (Moore et al., 1970). A second possibility is the oc-
61 
currence of suppressor cells which inhibit the response of 
the otherwise reactive cells to MTV. Both immune suppres-
sive mechanisms will be dealt with in Chapter v. 
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CHAPTER IV 
THE ROLE OF SPLEEN CELL SUBPOPULATIONS IN MTV-DIRECTED 
CELLULAR IMMUNITY 
To obtain more insight into the suppressive factors 
that are responsible for the depression in MTV-directed 
cellular immune reactivity that occurs when tumour growth 
progresses, it is necessary to first establish which immu-
nocytes react against MTV. 
For this purpose spleen cells from immunized DBAf mice 
were treated with crude cell separation techniques (Chapter 
II;6). The MTV-directed reactivity of the spleen cell sub-
populations was then established with the LS and the LAI-
assay. For these studies, the indirect variant of the LAI-
assay was employed, since a stepwise analysis of the in 
vitro immunological events is much easier to realize in 
this test than in the direct LAI-assay (Chapter II;3,4). 
Evidence is presented that the LS and LAI assays are 
both T cell dependent. It is well-known that macrophages 
are required for mitogen-induced T cell proliferation 
(Rosenstreich et al., 1976)i in this Chapter, we demon-
strate that macrophage-like cells also play a crucial role 
in the LAI assay. 
4.1. Mechanisms of MTV-induced LAIF production 
!h~ ~o!e_o! ~iff~r~n! ~ell_s~b£OEUla!i~n~. As men-
tioned in Chapter II, Holt et al. (1975) reported that the 
antigen-induced inhibition of adherence of leukocytes can 
be transferred to normal adherent cells by a soluble 
factor, LAIF, that is present in the supernatant of immune 
spleen cells incubated with the antigen. Our indirect test 
is based on this finding. According to the observations of 
63 
Table 11 
MTV-SPECIFIC LAIF PRODUCTION OF DIFFERENT CELL SUBPOPULATIONS PREPARED FROM IMMUNE 
SPLEEN CELLS AS MEASURED BY THE INDIRECT LAI ASSAY 
Cell subpopulation 
Spleen cells 
Macrophage-depleted 
spleen cells 
B cell-enrichedb 
T cell-enrichedb 
T cell-enriched 
and adherent cells 
a-SE: standard error 
b see text, Chapter II:6 
Exp. 1 
Incubation 
with RLV 
Incubation 
with MTV 
Average no. of adherent 
cells + SEa 
71.3 + 3.7 49.6 + 3.3 
44.6 + 1.6 43.2 + 1.4 
43.8 + 2.8 44.6 + 3.0 
27.9 + 2.5 29.6 + 1.9 
55.3 + 2.3 38.3 + 1.7 
* significant reduction of adherence (p ( Q.OOl) 
Exp.l Exp.2 Exp.3 
Reduction of adherence 
(%) 
30* 35* 25* 
3 2 3 
0 1 0 
0 2 0 
31* 27* 26 * 
Holt, the indirect LA! reaction can be abolished by pre-
treatment of the spleen cells with anti-theta-serum and 
complement. 
For this study, we used in each experiment pooled 
spleen cells obtained from at least 5 immunized DBAf mice. 
As antigen MTV-S, purified as described in Chapter !!.2, 
was used. In each experiment, the RLV control cells re-
ceived the same treatment as the cells incubated with MTV. 
First, we established which cell subpopulations are 
necessary for MTV-specific LAIF-production. T-cell enriched 
fractions were obtained by passage over a nylon wool 
column. Adherent cells were removed by plastic adherence; 
the adherent cells present in 20 x 10 6 spleen cells were 
allowed to attach to the surface of the plastic tubes in 
which the test was performed. After washing medium was 
added. When adherent cells in combination with T cell 
enriched cell fractions were tested, adherent cells were 
obtained in the same way; instead of medium, the T cell-
enriched fraction was added. B-cell enriched fractions were 
obtained by first removing the adherent cells; then the cell 
suspension was treated with anti-theta serum and comple-
ment. The cell subpopulations were then tested simultane-
ously. 
The results, summarized in table ll show that LAIF pro-
duction could be inhibited by pretreatment of the spleen 
cells with mouse anti-theta serum and complement. Negative 
results were also obtained with T cell-enriched fractions, 
and with spleen cell populations depleted of adherent 
cells. If aT cell-enriched fraction was added to adherent 
cells, a positive result was obtained. 
To determine whether direct cell-to-cell contact be-
tween T cell-enriched fractions and adherent cells is ne-
cessary for LAIF production, these cell populations were 
cultured so that exchange of soluble factors could take 
place, while the cells were separated by a Millipore fil-
ter: Adherent cells were allowed to attach to the bottom of 
plastic tubes (Falcon, 75 x 100 mm). Afterwards, sterilized 
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Table 12 
MTV-SPECIFIC LAIF PRODUCTION BY IMMUNE T CELL-ENRICHED CELL POPULATIONS AND ADHERENT 
CELLS WHEN CULTURED IN THE SAME MEDIUM BUT SEPARATED BY A MILLIPORE FILTER 
Culture method 
Cell populations 
mixed 
Cell populations 
separated by a 
Millipore filter 
* SE: standard error 
Exp. l 
Incubation 
with RLV 
Incubation 
with MTV 
Average no. of adherent 
cells + SE* 
21.2 + 0.9 16.1 + 0.5 
21.1 + l.O 15.0 + 0.4 
**all values were significant (p ( 0.001) 
Exp .1 Exp.2 Exp.3 
Reduction of adherence 
(%)** 
24 31 
29 34 
37 
38 
Millipore filters with a diameter of 47 mm and a pore size 
of 0.45 p (Millipore, Bedford, Mass.) were moistened in 
medium and pushed into the tubes in such a way that they 
became funnel-shaped. Only the point of the filter made 
contact with the underlying medium. One ml of a T cell 
enriched fraction was then transferred into the funnel-
shaped filter. After the incubation period, the filters 
were removed and the remaining cells were spun down; then 
the supernatant was tested. 
The results, summarized in table 12, demonstrate that 
LAIF production is not decreased if the cells are separated 
by a Millipore filter. Therefore, cell-to-cell comunica-
tion, mediated by soluble factors, is likely to trigger 
LAIF-production. 
To study the sequence of interactions between T cells 
and adherent cells, supernatant first incubated for 24 h 
with MTV and adherent cell cultures was added to a T cell-
enriched fraction. After another 24 h incubation period the 
supernatant was tested for LAIF-production. Also the 
reverse sequence of incubation (i.e. supernatant incubated 
with T cell enriched fractions transferred to adherent 
cells) was tested. Prior to adding a supernatant to a 
different cell population, the cells were washed two times. 
Surprisingly, both sequences of incubation yielded negative 
results. For this reason, the incubation scheme was ex-
tended: MTV was added to adherent cells; after a 24 h incu-
bation period, the supernatant was transferred to a T cell 
enriched fraction, and after another 24 h period of incu-
bation transferred to adherent cells again. After incuba-
tion, the resulting supernatant was tested for LAIF-pro-
duction. Also the sequence of transfer T cell enriched -
adherent cells - T cell enriched was tested. The RLV con-
trol supernatants were prepared in the same way. 
The results are presented in table 13. All combina-
tions shown on this table were tested simultaneously. The 
results clearly show that inhibition of adherence is 
achieved only when the following order of transfer was 
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Table l3 
EFFECT OF DIFFERENT SUPERNATANTS ON MTV-SPECIFIC IMMUNE ADHERENCEa. 
Production of 
supernatants by 
Tc + Ad 
T 
A 
T ..... fA 
A-T 
T- A - T 
A-T -A 
Exp. l 
Incubation 
with RLV 
Incubation 
with MTV 
Average no. of adherent 
cells + SEb 
88.9 + 1.7 57.1 + 3.7 
37.2 + 1.9 37.0 + 1.4 
38.7 + 3.3 37.4 + 1.0 
70.6 + 1.3 71.8 + 1.7 
80.5 + 2.4 83.8 + 2.1 
82.6 + 5.4 81.2 + 3.9 
110.0 + 5.2 58.5 + 4.1 
Exp.l Exp.2 Exp. 3 
Reduction of adherence 
(%I 
36 *e 40* 35* 
0 0 2 
3 l 4 
0 3 2 
0 0 l 
2 4 6 
47* 31 * 45 * 
~ incubation period with each cell subpopulation 
SE· standard error 
was 24 h 
~ T : T cell enriched subpopulations (Chapter II.6) 
A adherent cells 
e * p < 0.001 
f- arrow indicates "supernatant transferred to"; the final supernatant was 
transferred to indicator cells. 
used: adherent cells - T cells - adherent cells. 
The £O~e_of ~n~ige~. It is interesting to know whether 
antigen continues to play a role after the initial incuba-
tion with adherent cells, or whether cell-to-cell communi-
cation is exclusively mediated by the soluble factors pro-
duced by adherent cells and the T cells, referred to as 
SF1 and SF 2 , respectively. For this reason, the MTV was 
removed from the SF1 -containing medium by treatment with 
rabbit anti-MTV serum bound to Sepharose beads. 
For sterilization, these beads were left overnight at 
4° C in a 2 % sodium azide solution in PBS, and then 
washed 4 times in medium. After this treatment, the beads 
were still active in binding MTV, as was shown by the 
Sepharose bead immunofluorescence technique. The number of 
beads added to 1 ml of supernatant could bind approximately 
100 ~g of MTV. After the incubation period, the beads were 
spun down and the supernatant was transferred to T cells 
and then to adherent cells again prior to testing. 
The results, summarized in table 14, show that LAIF 
production induced by SF 1 is not decreased when the 
antigen is removed after the initial incubation of the 
adherent cells with MTV. Control experiments in which MTV 
was removed with the adsorbent prior to adding the medium 
to immune adherent cells showed that the production of 
SF1 was completely prevented. 
4.2. MTV-specific proliferating cells in the LS assay 
To investigate which cell subpopulation reacted with 
proliferation in the LS assay upon incubation with MTV, 
14 c-thymidine incorporation of different spleen cell-
subtractions after incubation with MTV was tested. Spleen 
cells were taken from immunized BALB/cfC3H and GR mice; 
MTV-S (Chapter II;2) was used as the test antigen. 
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Exp. 
no. 
1 
2 
3 
Table 14 
INFLUENCE OF REMOVING MTV FROM THE SF 1-CONTAINING SUPERNATANT ON THE RESULTING MTV-SPECIFIC LAIF PRODUCTION 
SF 1 depleted of MTV 
Average no. of Reduction of 
adherent cells + SE** adherence (%) 
45.8 + 4.0 45 
66.2 + 3.7 47 
53.8 + 5.0 42 
Untreated SF 1 
Average no. of 
adherent cells + SE 
32.5 + 6.8 
69.5 + 4.0 
59.8 + 3.2 
Reduction of 
adherence (%) 
61 
45 
36 
* Reduction-a-s compared to RLV control; all values were significant (p < 0.001) 
** SE: standard error 
Table 15 
MTV-SPECIFIC l4c-THYMIDINE UPTAKE OF VARIOUS SPLEEN CELL SUBPOPULATIONS OF IMMUNIZED MICE 
Experiment l 
Incubation with 
Mouse strain Cell population RLV 
cpm ± SEa 
BALB/cfC3H Lymphocytesb 2,237 + 712 
T-cell-enrichedc 1,652 ± 318 
8-cell-enrichedc 1,086 + 312 
GR Lymphocytes 5,161 + 561 
T-cell-enriched 1.721 + 203 
B-cell-enriched 2,640 + 416 
a SE: standard error 
b spleen cells depleted from adherent cells 
c Chapter II.6 
d *statistically significant (p ( 0.010) 
Exp. 1 Exp. 2 
Incubation with 
MTV Stimulation (%) 
cpm ± SE 
3,226 + 233 44 121* 
3,595 + 184 ll7*d 246* 
1,224 + 218 13 29 
15,889 + 249 211* 53 
7,273 + 567 322* 96' 
2,841 + 268 17 4 
Exp. 3 
87' 
154 * 
0 
74' 
137* 
2 
Table 16 
14c-THYMIDINE INCORPORATION OF T CELL-ENRICHED SPLEEN CELL SUBPOPULATIONS OF IMMUNIZED MICE, CULTURED WITH 
IMMUNE OR NORMAL ADHERENT CELLS 
Experiment 1 
Incubation with 
RLV 
Mouse strain Cell population cpm ~ SEa 
BALB/cfC3H T cell-enriched fractionsb 1,991 + 321 
GR 
and immune adherent cells 
T cell-enriched fractions 
and normal adherent cells 
T cell-enriched fractions 
and adherent cells 
T cell-enriched fractions 
and normal adherent cells 
~ SE: standard error 
Chapter II.6 
c riot significant 
d *'P ( 0.010 
e p ( 0.025 
2,173 + 207 
1,805 + 134 
2,157 + 288 
Incubation with 
MTV 
cpm + SE 
3,047 + 207 
3,001 _± 57 
3,698 + 325 
4,025 _± 178 
Exp.1 Exp. 2 
-- --
stimulation (%) 
soc 98*d 
46e 74* 
105* 145* 
87* 136* 
To obtain comparable results, the MTV-specific l4c-
thymidine uptake of T cell enriched and B cell enriched 
spleen cell fractions was compared to the 1 4c-thymidine 
uptake of spleen cells depleted from adherent cells (i.e. 
lymphocytes). The results, demonstrated on Table 15, 
indicate that the T cell-enriched fraction showed the 
highest proliferation as compared to the RLV-control, 
whereas the degree of proliferation observed with the same 
number of cells of the B cell-enriched population was 
neglegible. Even if stimulation of the lymphocytes was not 
significant, significant stimulation emerged when T cell-
enriched cell fractions were used. 
When immune adherent cells were added to the T cell-
enriched fraction proliferation was not increased, as 
compared to T cells to which normal adherent cells were 
added (Table 16). 
4.3. Discussion 
In the LAI-assay, pretreatment of the spleen cells with 
mouse anti-theta serum and complement completely abolishes 
the LAIF production, thereby confirming the results of Holt 
et al. (1975). However, aT cell-enriched fraction contain-
ing at least 60 % theta-positive cells also failed to in-
duce the LAI-reaction, while a positive result was found 
when adherent cells were added. We therefore conclude that, 
at least in the MTV system, both T cells and adherent cells 
are necessary for producing LAIF. The adherent cells which 
can be removed by the iron-magnet method or by adherence to 
plastic surfaces may well be monocytes (Grosser et al., 
1976). 
Marti et al. (1976), who performed the LAI assay with 
peripheral blood lymphocytes from breast cancer patients, 
could not find any evidence for a soluble mediator that is 
responsible for the inhibition of adherence, nor could 
Holan et al. (1974), who used rat lymph node cells. A 
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possible explanation for these negative results is the 
source of lymphoid cells used: preliminary results indicate 
that in the indirect assay lymph node and peripheral blood 
cells of immunized animals do not show a positive LAI-
reaction, whereas spleen cells do. Probably, one subpopula-
tion needed for the eventual release of LAIF is present in 
too low proportion in peripheral blood and lymph nodes. 
From the experiments in which T cells and adherent 
cells were cultured in the same medium, while the cells 
themselves were separated by a Millipore filter, and from 
the supernatant transfer experiments it can be concluded 
that direct cell-to-cell contact is not required for LAIF 
production, but that interaction is mediated by soluble 
factors. 
To detect which interactions between the adherent cells 
and the T cell enriched fractions had to take place for the 
production of LAIF, supernatant incubated with one of these 
cell fractions was transferred to another; the resulting 
supernatant was tested. Various sequences of incubation 
were tested. From our results, it became evident that LAIF 
production occurred when a) adherent cells were incubated 
with the antigen; b) the supernatant was transferred to T 
cell-enriched cell populations; and c) the supernatant of 
the latter was again transferred to adherent cells. 
Our results suggest the following sequence of reac-
tions: When antigen is presented to adherent cells, they 
release a soluble factor, which we shall call SF1 . When 
SF 1 interacts with T cells, these produce another soluble 
factor, SF 2 . When SF 2 interacts with adherent cells, 
they release LAIF, which is responsible for the inhibition 
of adherence of leukocytes (fig. 11). 
No significant decrease in LAIF production was found 
when antigen was removed from the SF1 containing medium; 
thus it is concluded that, after the initial incubation 
with adherent cells, soluble antigen is not longer re-
quired. One must bear in mind that part of the Ig-positive 
B cells have adherent properties; moreover, blocking and 
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antigen (±antibody) 
(a) ~ 
/(c) 
I SF2 
~ (d) 
LA IF 
Figu:r>e 11: Mechanisms of LAIF production 
(a) Antigen, whether or not complexed with antibody, contacts adherent 
cells; (b) upon this contact the adherent cells release a soluble 
factors SF1 , which reacts with T cells; (c) this event stimulates the 
T cells to release another soluble factor, SF2; (d) SF2 stimulates the 
adherent cells to produce LAIF, which inhibits the adherence of leuko-
cytes. 
enhancing properties of serum can be established with the 
LA! assay (Halliday and Miller, 1972). Thus it is possible 
that antibody produced in vitro by adherent B cells binds 
the added antigen; the ingestion of these complexes by 
macrophages may be the signal to produce SF 1 . It remains 
unclear whether antigen-antibody complexes are required for 
the release of the other soluble factors that are involved 
in this system. 
Also in the LS assay it was analysed which spleen cell sub-
population reacted upon incubation with MTV. From the expe-
riments on 14c thymidine incorporation with the spleen 
cell subpopulations, it can be concluded that the MTV-
specific reactivity in the LS assay observed in splenic 
cell cultures derived from BALB/cfC3H and GR mice immunized 
with MTV is due primarily to proliferation of T cells. 
The addition of adherent cells derived from immunized 
animals did not enhance the proliferation of T cell-en-
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riched cell fractions as compared to when normal adherent 
cells were added. It is therefore not likely that specifi-
cally primed macrophages are required in large guantitities 
for the induction of specific T cell proliferation. 
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CHAPTER V 
SUPPRESSIVE FACTORS INTERFERING WITH CELLULAR IMMUNE 
RESPONSES TO MTV IN TUMOUR BEARING MICE 
Immune reactivity to MTV declines during tumour growth 
(Chapter III). Like mentioned in Chapter !.4, several 
authors have reported the existence of suppressor cells 
with adherent properties, which inhibit the aspecific 
cellular immune response. In addition, it has been found 
that the cellular immune response in leukaemic patients 
could be enhanced by slight trypsinization of the imrnuno-
cytes. In many tumour systems, serum blocking factors that 
inhibit cellular immune reactivity have been established. 
we have therefore investigated whether such factors 
interfere with the MTV-directed cellular immune reactivity 
in tumour bearing mice. During these studies we detected 
that the following immune suppressive mechanisms are 
present during tumour development: 1) suppressor cells with 
adherent properties that inhibit the MTV-specific prolifer-
ation of T lymphocytes; 2) a suppressive factor covering T 
lymphocytes (and probably rnacrophages) and thus making them 
unresponsive in both the LAI and LS assays; 3) serum 
factors inhibiting LS and LAI reactivity. 
Evidence is presented that the latter two factors are 
probably antigen-antibody complexes. 
5.1. Suppressor cells with adherent properties 
To detect which cells influenced MTV-specific prolifer-
ationr T cell-enriched fractions from tumour bearers were 
tested in the LS assay in combination with adherent cells. 
For this purpose, the adherent cells present in 2.5 x 10 6 
spleen cells were allowed to adhere in the tubes in which 
77 
Table 17 
SUPPRESSION BY ADHERENT CELLS FROM TUMOUR-BEARING ANIMALS ON l4c-THYMIDINE INCORPORATION OF T CELL-ENRICHED 
SPLEEN CELLS INCUBATED WITH MTV 
donors of test cells 
Mouse strain Tumour weight 
BALB/cfC3H 
GR 
* SE: standard error 
(g) 
1.4 
3.8 
2.8 
4. 2 
T cell-enriched spleen cells 
adherent cells normal adherent 
from the same cells 
animal 
cpm _+ SE* cpm + SE 
l, 428 + 128 2,371 + 23 
l, 727 + 256 3,579 + 420 
1,025 + 76 2, 084 + 234 
l, 810 + 190 3,534 + 337 
inhibition 
I% I 
40 
52 
51 
49 
Significance 
p < 0.001 
p o. 025 
0.025 < p < 0.050 
0.005 < p < 0.010 
the LS assay was performed; the supernatant was then re-
moved and the adherent cells were washed three times with 
medium. The approximate number of adherent cells was esti-
mated by subtracting the number of cells that did not ad-
here from the original concentration. 
In both GR and BALB/cfC3H mice bearing large MTV-
induced tumours {2 g or larger), it was constantly observed 
that the T cell response was markedly depressed if adherent 
spleen cells derived from the same animals were added, as 
compared to cultures to which adherent cells derived from 
normal animals were added {table 17). When different con-
centrations of adherent cells derived from mice bearing 
large tumours were added to T cell-enriched fractions 
derived from mice bearing very small tumours, 14c-thymi-
dine uptake in the presence of MTV decreased gradually. 
This was not the case when adherent cells from normal ani-
mals were added (fig: 12). 
To determine whether the cellular hyporeactivity seen 
at a tumour weight exceeding 2 g (Chapter III) can be 
attributed to suppressor cells, individual BALB/cfC3H mice 
bearing tumours of varying sizes were tested for the pres-
ence of such cells. Spleen cells (0.5 x 106 ) derived from 
a tumour-bearing mouse were added to T cell-enriched frac-
tions from such animals. Cultures to which normal spleen 
cells were added in the same concentration served as con-
trols. Both sets of cultures were incubated with MTV and 
per cent inhibition of 14c-thymidine incorporation was 
calculated. The results are shown in fig. 13. From the 
resultsr it is clear that suppressor cells are present in 
animals bearing small tumours: the first significant inhi-
bition is seen at a tumour weight of 0.5 g. Greatest inhi-
bition is seen at a tumour weight between 0.5 and 1.5 g; at 
about 4 g, considerable inhibition also occurs. 
In animals bearing small tumours, removal of adherent 
cells lead to a considerable increase in M~V-induced pro-
liferation. In animals bearing large tumours, however, 
spleen cell cultures containing suppressor cells sometimes 
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Table 18 
INFLUENCE OF REMOVAL OF ADHERENT SUPPRESSOR CELLS ON 14 C-THYMIDINE INCORPORATION BY SPLEEN CELLS OF 
BALB/cfC3H MICE BEARING TUMOURS OF VARYING SIZE 
Tumour weight Cell population 
1. 40 Spleen cells 
T cell-enriched 
2. 90 Spleen cells 
T cell-enriched 
* SE: standard error 
**NS: not significant 
Incubation with 
RLV 
cpm + SE* 
3,464 + 127 
2,650 + 664 
5,611 + 342 
2,446 + 368 
Incubation with 
MTV 
cpm + SE 
4,272 + 106 
6,747 + 380 
3, 8 56 + 98 
2,216 + 929 
Stimulation 
I% I 
24 
155 
0 
Significance 
0.010 (p < 0.005 
0.005 (P ( 0.001 
0.010 (p < 0.005 
NS** 
per cent odhereM cell> added 
Figure 12: 
Inhibition of cells responding to MTV by adherent suppressor cells in 
the LS assay 
14
c-thymidine incorporation of T cell-enriched fractions derived from 
3 BALB/cfC3H mice bearing small tumours (average 0.27 g), when varying 
numbers of adherent suppressor cells derived from 4 BALB/cfC3H mice 
bearing large tumours (average 3.10 g) were added. 
-----: normal adherent cells added; -----: suppressor adherent cells 
added. 
Vertical bars indicate SE of triplicate cultures. The RLV control was 
6.10- 3 cpm. Shown in the figure are the results of one out of two ex-
periments. The results of both experiments were similar. 
gave significantly lower cpm values than did the RLV-con-
trol. Removing the suppressor cells by adherence to plastic 
surfaces gave about equal values for MTV and RLV cultures; 
even then, no MTV-specific proliferation was obtained. The 
average MTV-specific per cent stimulation of T cell-en-
riched fractions of 9 animals with small tumours (average 
0.9 ± 0.2 g) was 83.1, and varied from 23 to 154; for 10 
animals tested with large tumours (average 3.5 ± 0.2 g) 
this value was 15.2 with a variation of 0-62 %. Some repre-
sentative results are shown on table 18. 
Neither antigen nor antibody could be detected on the 
surface of adherent suppressor cells by membrane immuno-
fluorescence studies. 
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Table 19 
INFLUENCE OF EXTENSIVE WASHING AND TRYPSINIZATION ON MTV-SPECIFIC 14c-
THYMIDINE INCORPORATION OF INITIALLY UNRESPONSIVE T CELL-ENRICHED SPLEEN CELLS 
FROM TUMOUR BEARING BALB/cfC3H MICE* 
T cell-enriched spleen cells 
Treatment of cells Incubation with Incubation with 
RLV !1TV 
cpm cpm 
3 washings 2,587 1,884 
8 washings 2,169 3,745 
Trypsinization 2,297 5,192 
* 
** 
all values represent the mean of five identical experiments. 
SE~ standard error of the mean values of five experiments 
Percentage 
stimulation {+) 
or inhibition (-) 
+ SE** 
- 25 + 8 
+ 73 + 23 
+126 + 24 
160 
0 ® 0 
~ 140 ® 
' ® 0 100 
" 
® 
® 
• 60 
• • • 
• ® 
•• • 20 • 
® 
• 
tumour weight in groms 
Figure 13: 
Distribution of adherent suppressor cells in mice bearing tumours of 
varying size 
The inhibition of 14c-thymidine incorporation of T-cell enriched 
fractions from spleen cells of individual tumour-bearing BALB/cfC3H 
mice, caused by the addition of adherent suppressor cells derived from 
the same animal. Inhibition was expressed as percentage of identical 
cultures to which adherent cells derived from normal animals were 
added. 0 : inhibition is not significant; ® : inhibition is signifi-
cant (p < 0.025). 
5. 2. Suppressive factor covering spleen cells 
Since the fluctuations in the number of suppressor cells 
did not show a reverse correlation with the variation in 
the immune response during tumour growth, and since, in 
animals with very large tumours 1 removal of suppressor 
cells did not lead to recovery of specific anti-MTV pro-
liferation1 other inhibitory factors must be involved. It 
was investigated whether T cell unresponsiveness was due to 
coating of the cells with a suppressive agent. Therefore, T 
cell-enriched spleen cells were extensively washed or 
slightly trypsinized prior to testing. 
T cell-enriched spleen cell fraction from tumour 
bearing BALB/cfC3H mice were unresponsive to MTV in the LS 
test after three washings. Significant proliferation oc-
curred after mild trypsinization or after five additional 
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Table 20 
EFFECT OF PREINCUBATION WITH WASH FLUID FROM UNRESPONSIVE SPLEEN CELLS ON THE 
MTV-SPECIFIC 14 C-THYMIDINE INCORPORATION OF IMMUNE T CELL-ENRICHED SPLEEN 
CELLS* 
Preincubation 
with wash 
fluid from 
Normal spleen cells 
Spleen cells of tumour 
bearing BALB/cfC3H 
mice 
Spleen cells of tumour 
bearing BALB/c mice 
Immune T cell-enriched spleen 
cells 
Incubation Incubation 
with RLV with MTV 
cpm cpm 
2,052 4,777 
2,537 4,974 
3,088 1,552 
3,333 L 665 
Percentage 
stimulation (+) 
or inhibition (-) 
+ SE** 
+132 + 12 
+ 96 + 9 
- 50 + 7 
- 50 + 5 
* all values represent the mean of four identical experiments. 
** SE: standard errors of the mean value from four identical experiments 
washings (Table 19). To confirm the hypothesis that washing 
removes a suppressive factor from the lymphocytes, the T 
cell fractions from animals with large tumours were washed 
eight times. T cell fractions (106 cells) from immunized 
animals were incubated with the wash fluid derived from 5 x 
106 cells for 1 h at 37° C prior to testing. From the 
results in Table 20 it becomes evident that the wash fluid 
of the cells from tumour bearing animals inhibits MTV-
specific proliferation, while the wash fluid derived from 
normal BALB/c spleen cells has no effect. 
In all of the cases of BALB/cfC3H mice with tumours, 
trypsinization led to an augmentation of proliferation. The 
average increase was 84 %. Tumour weight varied between 
0.16 and 4.20 g. 
We also investigated the influence of the washing and 
trypsinization procedures on the indirect LA! assay. LAIF 
production by unreactive spleen cells from tumours bearing 
BALB/cfC3H mice was not increased by trypsinization or re-
peated washings prior to testing. The significance of this 
finding remains, however, doubtful, since the reactivity of 
spleen cells from immunized animals was abolished after 
these treatments (table 21). It is possible that this in-
activation is caused by removal of serum factors from the 
cells, which are required for LAIF-production. Therefore, 
LAI-tests were performed with trypsinized immune spleen 
cells after the addition of complement, and in the presence 
of 10 % normal mouse serum. However, these treatments did 
not lead to recovery of MTV-specific LAIF-production. 
However, wash fluid of 100 x 106 spleen cells from 
tumour-bearing mice can inhibit the LAIF production by 20 x 
106 spleen cells from immunized animals; the washings of 
normal cells had no effect on LAIF-production by immune 
spleen cells (Table 22). Probably, a similar suppressive 
agent as in the LS assay plays a role in the unresponsive-
ness of tumour-bearing animals in this test. 
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Table 21 
INFLUENCE OF EXTENSIVE WASHING AND TRYPSINIZATION ON LAI REACTIVITY* OF SPLEEN CELLS 
FROM TUMOUR BEARING AND IMMUNIZED BALB/c MICE 
Donors 
Tumour bearing BALB/cfC3H mice 
Immunized BALB/c mice 
No. of 
experiments** 
6 
4 
* Established by the indirect LAI-assay. 
Spleen cell responses 
Treatment of cells Incubation with Incubation with 
RLV MTV 
no. of adherent cells 
3 washings 92.1 83.3 
8 washings 67.9 66.2 
Trypsinization 57.9 56.8 
3 washings 92.8 68.8 
8 washings 124.1 129.8 
Trypsinization 88.0 86 .o 
**Each figure represents the mean of the indicated number of identical experiments. 
***SE: standard error of the mean value of the indicated number of identical experiments. 
Reduction 
of adherence 
{%) + SE*** 
9 ± 2 
2 + 2 
2 + 2 
25 + 3 
2 + 3 
Table 22 
EFFECT OF PREINCUBATION WITH WASH FLUID FROM UNRESPONSIVE SPLEEN 
CELLS ON THE MTV-SPECIFIC LAI REACTIVITY* OF IMMUNE SPLEEN CELLS** 
Preincubation 
with wash 
fluid from 
Normal spleen cells 
Spleen cells of tumour 
bearing BALB/cfC3H 
mice 
Spleen cells of tumour 
Immune spleen cell responses 
Incubated with 
RLV 
Incubated with 
MTV 
(no. of adherent cells) 
85.9 65.8 
24 3. 5 19 9. 9 
265.7 273.8 
105.8 113.4 
__ b~_~_!"i~_g BAL_!?jc mic_e ___ _ 
* Established by the indirect LAI assay. 
Reduction 
of adherence 
(%) _.J:- SE*** 
23 + 4 
18 + 2 
** Each figure represents the mean of four identical experiments. 
*** SE: standard error of the mean value of four identical experiments. 
Table 23 
INFLUENCE OF SERUM FACTORS FROM TUMOUR BEARING BALB/cfC3H MICE ON LAI REACTIVITY* OF IMMUNE 
SPLEEN CELLS 
Immune spleen cell responses 
Tumour weight of 
serum donor (g) normal serum + MTV test serum + MTV 
(no. of adherent cells~ SEa) 
l.l 75.0 + 4.0 
2.0 64.3 + 3.9 
2.1 60.0 + 2.1 
3.0 82.3 + 2.3 
6.5 72.8 + 2.2 
6.8 54.8 + 1.6 
*Established by the indirect LA! assay 
asE: standard error for 10 wells 
bquotient y: Chapter !!,4 
eNS: not significant 
104.5 + 3.9 
71.5 + 3.8 
71.7 + 2.5 
124.5 + 3.3 
83.0 + 4.5 
64.1 + l.S 
Significance Quotient yb 
p < 0.001 l. 39 
NSc l.ll 
p < 0.010 l. 20 
p < 0.001 l. 51 
NS l.l4 
p < 0.001 1.17 
5.3. Serum blocking factors 
The presence of serum factors that block or enhance cellu-
lar immunity can be easily established with the indirect 
LAI assay. We tested 15 sera from tumour bearing BALB/cfC3H 
mice. In all tests, quotient y was higher than 1, which in-
dicates blocking. The decrease in adherence when test serum 
was added was significant in about one-half of the cases. 
Blocking activity of the sera showed no relation to tumour 
weight (Table 23). 
Sera that had blocking activity in the LAI assay also 
inhibited MTV-specific proliferation by immune T cell-en-
riched cell fractions. This is shown in Table 24. 
5.4. Presence of MTV and anti-MTV antibodies in the suppressive factor 
and the blocking serum 
The nature of the suppressive factors in wash fluids and 
sera from tumour-bearing mice was investigated with the 
Sepharose bead immunofluorescence assay. Prior to testing, 
the mouse sera were concentrated lOx by an Arnicon-concen-
trator; the washings were derived from 200 x 10 6 cells 
per ml and concentrated 20x with the same technique. When 
the fluorescence of the lowest dilutions was about three 
times higher than background values, the samples were 
scored as positive(+); stronger fluorescence was recorded 
as ++, and when fluorescence was about equal to the posi-
In both tive control the samples were 
samples MTV could be detected 
scored as +++. 
(Table 25), although the 
levels were generally low. No MTV was detected in serum and 
wash fluid samples from normal animals. These results were 
confirmed by radioimmunoassay, kindly performed by Dr. A.A. 
Verstraeten {Netherlands Cancer Institute, Amsterdam). 
By means of the Sepharose bead immunofluorescence assay 
anti-MTV antibodies were also detected in the spleen cell 
wash fluids from the tumour bearing mice, but were absent 
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Table 24 
INFLUENCE OF SERUM FROM TUMOUR BEARING MICE ON MTV-SPECIFIC PROLIFERATION OF IMMUNE 
T CELL-ENRICHED FRACTIONS 
Serum donors 
Tumour bearing BALB/cfC3H mice 
Tumour bearing BALB/c mice 
no. of 
experiments* 
4 
2 
Immune T cell-enriched fraction 
responses 
normal serum 
+ MTV 
cprn 
3,834 
3' 6 20 
test serum 
+ MTV 
cprn 
2,738 
2,442 
* Each figure represents the mean of the indicated number of identical experiments. 
** SE: standard error of mean value of the indicated number of experiments 
Percentage 
inhibition 
+ SE** 
-29 + 4 
-32 + 12 
in that from normal BALB/c animals. The serum from tumour 
bearing BALB/cfC3H mice was positive for the anti-MTV anti-
bodies, but the serum from tumour bearing BALB/c mice was 
negative- similar to sera from normal mice. Also the anti-
body levels found in the wash fluids and sera from tumour-
bearing animals were rather low, 
5.5. Discussion 
In the present study, it was demonstrated that the MTV 
specific response in tumour bearing animals may be depres-
sed by the presence of adherent cells. Increasing the cell 
density by adding an equal number of normal adherent cells 
had no inhibitory effect; therefore, it is not likely that 
the suppressive effect is due to a quantitative change in 
the spleen cell macrophage population of the tumour bearing 
mice (Kruisbeek and Van Hees, 1977). The suppressive effect 
was already seen when about 0.5 % adherent suppressive 
spleen cells were added to a cell population responding to 
MTV and about 5 % was enough to reach the maximal inhibit-
ory effect. These results are in accord with those of 
Glaser et al. (1975) in rats bearing progressively growing 
Gross leukemia virus induced tumours. 
Kirchner et al. (1974, 1975) observed a good correla-
tion between the growth pattern of Moloney sarcoma virus-
induced tumours and adherent suppressor cells; these cells 
were detected before the tumour had reached an appreciable 
size. In our investigation, suppressor cells could already 
be demonstrated at a tumour weight of 0.5 g. The greatest 
inhibitory 
and 1.5 g; 
effect was seen at a tumour weight between 0.5 
there was also a considerable 
g. The decline in spleen cell reactivity 
suppression at 4 
in the LAI and LS 
test when the tumour exceeds one gram in weight can be 
attributed to an increasing inhibition by suppressor cells. 
At 2 g, when the spleen cell activity in the LS test is at 
a minimum {Chapter III), the maximum inhibition by the 
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Table 2 5 
PRESENCE OF 11TV AND ANTI-11TV ANTIBODIES IN SUPPRESSIVE AGENTS AS 
MEASURED BY THE SEPHAROSE BEAD U1MUNOFLUORESCENCE METHOD* 
Sample 
Serum from 
Normal BALB/c 
Tumour bearing BALB/cfC3H 
Tumour bearing BALB/c 
Wash fluid of spleen cells from: 
Normal BALB/c 
Tumour bearing BALB/cfC3H 
Tumour bearing BALB/c 
Binding to 
anti-MTV 
antibodies 
+ 
++ 
+ 
+ 
Binding to 
MTV 
+ 
+ 
+ 
* When the fluorescence of the lowest dilutions was about three times 
higher than background values, the samples were scored as positive 
(+); stronger fluorescence was recorded as++, and when fluorescence 
was about equal to the positive control the samples were scored as 
+++. 
suppressor cells has already disappeared. 
Removal of adherent cells did not resuslt in a signi-
ficant MTV-directed T cell response at heavy tumour weights 
in most cases. Probably, suppression by the adherent cells 
is gradually replaced by suppression by antigen-antibody 
complexes during tumour growth. 
The mode of action of suppressor cells remains unclear. 
We could not detect antigen or antibody on the surface of 
the suppressor cells by membrane immunofluorescence 
studies. Eggers and Wunderlich (1975) found no evidence for 
the mediation of suppression by soluble factors. 
We did not investigate whether the suppressor cells in 
the MTV-system are adherent T cells. Until now only aspeci-
fically suppressive T cells with adherent properties have 
been recognized (Waksman, 1977). Suppressor cells are 
generally found in cases in which animals are overloaded 
with antigen and the possibility must be considered that 
they are part of a tolerance inducing mechanism that is 
activated when the immune system is confronted with excess 
tumour antigen. 
It was demonstrated that MTV-specific proliferation is 
greatly increased when T cell-enriched cell fractions from 
tumour bearing mice are extensively washed; slight trypsi-
nization of the cell surface resulted in even higher 
responses. Medium in which the unresponsive spleen cells 
from tumour bearing donors were washed repeatedly contained 
factors which suppressed the MTV-specific proliferation of 
immune T cell-enriched fractions. 
In our system trypsinization and repeated washings 
completely abolished the LAI reactivity of immune spleen 
cells. This deficit could not be restored by adding comple-
ment or by performing the test in 10 % normal mouse serum; 
possibly a receptor necessary for the reaction, in which 
cell communication is mediated by soluble factors (Chapter 
IV), is removed or destroyed by these treatments. However, 
the washings of spleen cells from tumour bearers inhibited 
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the LAI reactivity of untreated spleen cells from immunized 
donors. This indicates that LAI reactivity can be blocked 
by suppressive factors attached to the cell surface Of 
immunocytes from tumour-bearing animals. 
Factors that block cellular reactivity are also present in 
the serum of tumour bearing mice; these factors again inhi-
bited both the MTV-specific LAI reactivity and prolifera-
tion. 
With the Sepharose bead immunofluorescence assay it was 
established that the blocking serum as well as the wash 
fluids from spleen cells of tumour bearers contained MTV, 
whereas serum and wash fluid derived from normal animals 
did not. The wash fluid and one of the blocking sera of 
tumour bearers also contained anti-MTV antibodies. Most 
likely, both suppressive mechanisms are due to antigen-
antibody complexes. The levels of MTV antigens and anti-MTV 
antibodies were very low, but this is likely to be due to 
the immune complexes interfering with the amount of antigen 
and antibody measured in this system (Matthews et al., 
1975). 
Many authors have suggested that blocking factors in 
sera of individuals with cancer are the result of free 
antigen or immune complexes. Gorczynski et al. (1975) 
presented evidence that both free antigen and antigen-
antibody complexes mediate tumour-specific blocking, 
whereas nonspecific blocking is mediated by only antigen-
antibody complexes. They also suggested that the suppres-
sive action of adherent cells is mediated by the release of 
antigen-antibody complexes in culture. 
At the moment there is no insight into the role of 
immune complexes in immunodepression. There is a growing 
body of evidence that in immune response mechanisms cell-
to-cell interactions are often mediated by soluble factors; 
to exert their influence 1 all of these factors need to 
interact with the cell membrane. It is tempting to specula-
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te that the suppressive effects are due to an excess of 
antigen-antibody complexes: Antibody and antigen, whether 
or not complexed, will bind to the Fe and antigen receptors 
on lymphoid cells. When many immune complexes are in the 
circulation, these may subsequently attach to the antigen, 
antibody, or complexes bound on the cell membrane. When 
this process continues, at the end the cell will become 
covered with a reticulated formation which mask lymphokine 
acceptor sites. 
The question as to why macrophages do not phagocytose 
these immune complexes (McKeever et al., 1976) is of 
crucial importance from both a practical and a theoretical 
point of view. 
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CHAPTER VI 
MTV-PROTEIN VACCINE: INDUCTION OF ANTIVIRUS IMMUNITY AND 
ENHANCEMENT OR INHIBITION OF TUMOUR-SPECIFIC 
TRANSPLANTATION RESISTANCE 
Vaccination with oncoviral subunit proteins may protect 
mice against tumour development. In the MTV system several 
vaccination studies with tumour antigens have been per-
formed. However, these studies yielded conflicting results: 
some experiments resulted in protection against mammary 
tumour development, whereas other trials led to accelerated 
tumour development (Chapter I;S). We were interested in the 
question whether successful vaccination can be achieved by 
treatment with the major membrane glycoprotein of MTV, 
gp52, which is also expressed on the mammary tumour cell 
membrane. At the time these studies were started, there 
were no known methods to purify gp52; therefore, these 
vaccination experiments were performed with an MTV-protein 
fraction approximately 60 % of which consisted of gp52 
(Chapter II;8). This vaccine was derived from MTV-S. 
Several doses of this protein fraction were employed. 
Studying the effect of a given vaccination procedure on 
spontaneous tumour development requires long-term experi-
ments, and is complicated by the need to force breed the 
mice. Therefore, in this exploratory study we used the take 
of transplanted tumours as a measure for prophylaxis 
against spontaneous tumour development. Most of these 
investigations were performed with the DBAf leukaemia Ll210 
which grows in ascites form and carries MTV antigens 
(Radzikowski et al., 1972). The advantage of this cell 
line is the rapidity of tumour testing and the quantitative 
aspects of the assay. A few days' delay in animal kill can 
be expressed in terms of per cent kill of the inoculated 
tumour cells (Skipper et al., 1964). However, the Ll210 
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might represent a very artificial system, with little 
relevance to the control of spontaneous mammary carcino-
genesis. We therefore also studied the induction of trans-
plantation resistance in BALB/c mice to an MTV-0 induced 
mammary tumour which has the disadvantage of a long ob-
servation period. We used alum and !PM as adjuvants; con-
trols were treated with the adjuvant alone. 
Since the vaccination procedures might induce immune 
suppressive mechanisms, it was important to establish the 
immunologic events after the vaccination had been per-
formed. The immune response was therefore monitored on days 
12 and 20 after vaccination. MTV-specific cellular immune 
reactivity and the presence of serum blocking or enhancing 
factors was established by means of the LAI assay. The 
presence of anti-MTV-antibodies was established by means of 
membrane immunofluorescence. At the time of vaccination, 
the mice were 10-12 weeks of age. All vaccines were inject-
ed intraperitoneally. The appearance of the 11210 leukaemia 
and mammary tumours in the mice was established as des-
cribed in Chapter !!;8. 
6.1. Latency period of twnours after injection and influence of adju-
vants 
For the estimation of the effects of adjuvants and vaccine 
on tumour cell kill the latency period between injection 
and appearance of the two neoplasms first had to be 
determined. The presence of tumours was established as 
described in Chapter !!;8. Fig. 14a presents the average 
latency period (in weeks) of MTV-0 induced mammary tumours 
in the BALB/c strain; the latency period is plotted against 
the number of tumour cells in the inoculum. The latency 
period was linearly related to the logarithm of the cell 
inoculum. When 106 cells were grafted, tumours appeared 
within 4 weeks. All of the animals produced tumours when 
104 cells were inoculated, but the average latency time 
was 7 weeks. When 103 cells were injected, 33 % of the 
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animals developed tumours within the observation period of 
30 weeks. 
In our experiments, the 11210 leukaemia showed a rapid 
killing of the grafted animals (fig. 14b). One log differ-
ence in cell number caused a difference of 1 - 1.5 days in 
the killing of the animal. At low cell numbers (below 100) 
many survivors were noted up to 5 weeks; with 50 cells 60 
%, and with 25 cells 80 % of the animals survived. The 
latent period in the animals that developed tumours was 
then considerably lengthened. This deviation from usual 
titration patterns of 11210 (Skipper et al., 1964) was 
probably due to the in vitro cultivation of the line (P. 
Lelieveld, personal communication). 
The effect of 50 pg IPM on the latency period after 
inoculation with 10 4 , 10 3 or 102 11210 cells corres-
ponded with approximately a 1-day delay. There were no 
survivors in any group. This indicates that not a given 
number, but a given proportion of the inoculated 11210 
cells is killed by the activated immune system. For this 
reason it seemed reasonable to express the protective 
effect of a given vaccination procedure in percentage kill 
of the inoculated tumour cells. When accelerated growth of 
the tumour occurred, we expressed this in percentage "gain" 
of the inoculated tumour cells (i.e. less tumour cells were 
killed by the immune system in vaccinated animals than in 
the controls). 
The effect of injection with alum only is presented in 
Table 26. For both the mammary tumour and the leukaemia, 
the latency period seemed to be considerably lengthened. On 
the basis of fig. 14r the per cent kill of inoculated 
tumour cells has been extrapolated. For the leukaemia this 
was approximately 40 % at different doses of alumj only 
when a dose of 100 ug was employed less protection was 
observed. A 90% kill of inoculated tumour cells was found 
for the mammary tumour given 5 ~g alum, but at higher doses 
of this adjuvant the kill rate was decreased. Since the 
adjuvants influenced tumour growth, in all experiments 
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Table 26 
EFFECT OF INJECTION OF DIFFERENT DOSES OF ALUM ON GROWTH OF TUMOUR CELLS TRANSPLANTED 20 DAYS AFTER INOCULATION 
Strain 
BALB/c 
DBAf 
Tumour 
mammary 
tumour 
Ll210 
leukaemia 
Dose of 
alum 
pg 
---
5 
50 
500 
0.5 
5 
50 
100 
No. of 
inoculated 
cells 
104 
103 
104 
103 
100 
250 
200 
100 
250 
50 
Survival 
Tb 
0/7 
5/7 
3/10 
2/5 
2/5 
0/7 
0/5 
0/5 
0/13 
5/7 
uc 
0/9 
3/9 
0/9 
3/9 
0/10 
0/10 
0/10 
0/10 
0/10 
8/14 
Average latency perioda 
T u 
9.7 + 0.8 wkd 7.0 + 0.2 wk 
7.0 + 0.2 wk 
13.2 + 1.0 days 
13.6 _± 0.3 dd 12.8 _± 0.0 days 
14.3 + o.o d 12.9 ~- 0.0 days 
14.2 _± 0.3 d 13. 2 + 1. 0 days 
13.2 + 0.1 d 12.8 ± 0.0 days 
a values are means+ SE. The presence of tumour was established as described in Chapter II.B 
b T = treated animals 
c U =untreated animals: figures derived from figure 14. 
d wk = weeks; d = days. 
Calculated 
cell 
kill, % 
-
90 
50 
90 
10 
45 
64 
66 
30 
40 
17 
10 6 
-<>-- 106 .. 
\ a \ b ~ 1o 5 105 u 
--+-- ~ .. 
-" ~. \ ~ E E 2 104 2 ' ' 104 u u 
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Figure 14: 
Latency periods until time of tumour appearance after inoculation with 
various numbers of tumour cells 
Horizontal bars indicate standard error of the average time of tumour 
appearance (mammary tumour) or mortality of mice (Ll210) as calculated 
from 9 (A) or 10 (B) animals. Establishment of tumour appearance: see 
Chapter II; 8. 
A: Average latency of tumour appearance in 12-week-old female BALB/c 
mice after sc inoculation with tumour cells derived from an MTV-0 
induced tumour. 
B. Average survival time of 12-week-old female DBA£ mice after ip inocu-
lation with L1210 cells grown at least 2 days in vitro. 
-----: without treatment of mice; -----mice given ip injections of 
50 ug !PM 20 days before inoculation with tumour cells. 
described below the controls were treated with the adju-
vant~ 
6.2. Effect of vaccination on the growth of transplanted mammary 
tumours in BALB/c mice 
The results are summarized in Table 27. The challenge dose 
was varied to avoid too much survival in the control 
groups, in which the varying doses of alum had a protective 
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Table 27 
EFFECT OF INJECTION OF DIFFERENT DOSES OF A GP52-ENRICHED MTV PROTEIN FRACTION ON GROWTH OF TRANSPLANTED MAMMARY TUMOUR 
CELLS IN BALB/c MICE 
Group 
no. 
2 
3 
4 
Treatment 
1 pg MTV protein 
and 5 pg alum 
10 pg MTV protein 
and 50 pg alum 
10 pg MTV protein 
and 50 )-19 alum; 2 
boosts of 1 pg MTV 
protein 
100 }-19 MTV protein 
and 500 pg alum 
No. of 
inoculated 
cells 
--
104 
103 
104 
104 
103 
Survival Average latency period in weeksa 
vb cc v c Significance 
--
--
0/7 0/7 20.3 + 2.6 9.7 + 0.8 0. 0 OJ (p (0.005 
4/7 5/7 
4/7 2/5 
3/7 1/5 
0/5 2/5 ll.l + 0.3 16.2 + 0.4 p < 0.001 
a Values are means.+ SE of weeks of tumour appearance; tumours were established as described in Chapter II.S 
b V = animals treated with MTV protein and adjuvant 
c C = control animals, treated with adjuvant alone 
Calculated 
cell kill 
or gain {+) '% 
--
-99.9 
+30 } -12 
-42 
-so 
+40 
(-) 
effect. As compared to the control given alum alone, the 
vaccination with 1 pg MTV protein fraction enriched for 
gp52 led to a significant delay in the onset of the 
transplanted tumours {20 vs. 10 wk). This corresponded with 
a 3-log kill (99.9 %) of the inoculated tumour cells. When 
10 ~g of this vaccine was injected, no clear effect was 
observed. An additional booster dose of 1 pg gp52 on days 7 
and 14 had no significant effect. When 100 pg of the 
vaccine was used, tumours appeared considerably earlier in 
the vaccinated animals than in the controls. No influence 
on tumour growth was observed when BALB/c mice, given 
injections of l and 100 ~g gp52-enriched protein 
precipitated on alum, were challenged sc with 10 4 MOPC-
315 plasmacytoma cells {average latency period with 1 pg: 
19.7 days; controls, 19.5 days; with 100 pg: 19.7 days; 
controls, 19.6 days). 
6.3. Effect of vaccination on mortality of L1210 leukaemia in DEAf 
mice 
Table 28 summarizes the results obtained with alum as an 
adjuvant. Again, the challenge dose was varied to avoid too 
much survival in the control groups due to the protective 
action of the adjuvants. When complete virus, disrupted by 
freezing and thawing ten times, was used as antigen, doses 
of both 1 and 10 pg tended to induce a slight protection. 
When the gp52-enriched protein fraction was used, how-
ever, tumour growth was already accelerated at very low 
doses (0.1 and l pg). The high dose of 80 »9 also enhanced 
tumour growth; only 10 pg was protective. 
The results obtained with !PM as an adjuvant are out-
lined in Table 29. When 50 pg !PM was used, a protective 
effect, which diminished with an increasing dose of virus 
protein, could be observed for the MTV protein vaccine. 
However, when different doses of gp52 were injected with 
100 pg !PM, death was accelerated. 
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Table 28 
EFFECT OF INJECTION OF DIFFERENT DOSES OF ANTIGEN PRECIPITATED ON ALUM IN DBAf MICE ON GROWTH OF Ll210 LEUKAEMIA 
no.of survival Average days of survivala Calculated 
Group Treatment inoculated cell kill I- I 
no. cells vb cc v c Significance of gain (+) ,% 
---
1 1 ~g disrupted virus 250 1/5 0/7 14.0 + 0.1 13.6 + 0.3 NSd -20 
and 5 pg alum 
2 10 ~g disrupted virus 250 0/5 0/13 14.0 + 0.3 13.2 + 0.1 p < 0.010 -15 
and 50 pg alum 
3 0.1 pg MTV-protein 100 1/10 2/5 +50 
and 0.5 )-19 alum 
4 1 )19 MTV-protein 100 0/10 0/5 13.1 + 0. 2 14.2 + 0.3 p < 0.010 +30 
and 5 pg alum 
5 1 pg MTV-protein and 200 0/9 0/5 14.0 + 0.0 14.3 + 0.0 p < 0.001 +10 
5 pg alum; 1 boost 
1 )-19 MTV-protein 
6 10 ~g MTV-protein 250 0/8 0/13 14.0 + 0. 3 13.2 + 0.1 p < 0.001 -15 
and 50 }J9 alum 
7 80 )19 MTV protein 50 l/8 5/7 +80 
and 100 pg alum 
a values are means~ SE; death was taken as a measure for tumour development. 
b v = animals treated with antigen and adjuvant 
c c = control animals treated with adjuvant alone 
d NS = not significant 
Table 29 
EFFECT OP INJECTION OF DIFFEREN'l' DOSES OF A GP52-ENRICHED MTV PROTEIN FRACTION AND IPM IN DBAf MICE ON GROWTH OF Ll210 
LEUKAEMIA 
No.of 
inoculated 
cells 
Survival Average days of survivala 
Group 
no. 
1 
2 
3 
4 
5 
Treatment 
0.1 rg MTV protein 
and 50 f-19 IPM 
1 f-ig MTV protein 
and 50 pg IPM 
80 pg MTV protein 
and 50 }Jg IPM 
1 }Jg MTV protein 
and 100 pg IPM 
10 pg MTV protein 
and 100 pg IPM 
100 
100 
50 
200 
200 
vb cc v c 
2/10 0/5 16.9 + 0.6 14.9 + 0.2 
0/10 0/5 16.3 + 0.5 14.9 + 0.2 
6/10 4/7 
0/9 1/6 14.9 + 0.5 15.9 + 0.3 
0/9 1/6 13.4 + 0.2 15.9 + 0.3 
a values are means ~ SE; death was taken as a measure for tumour appearance, 
b v = animals treated with antigen and adjuvant 
c C ~ control animals treated with adjuvant alone 
d NS = not significant 
Significance 
p 0. 0 25 
NSd 
NS 
p < 0.001 
Extrapolated 
cell kill (-) 
or gain (+),% 
-20 
-10 
- 5 
+10 
+25 
Table 30 
IMMUNOLOGIC REAC'l'IVITY AFTER TREATMENT WI'rH VACCINES BEFORE AND AFTER SUBSEQUENT CHALLENGE WITH TUMOUR CELLS IN 
BALB/c MICEa 
Group 
1 
2 
3 
4 
Vaccines 
l pg MTV protein 
and 5 pg alum 
10 pg MTV protein 
and 50 }Jg alum 
10 pg MTV protein 
and 50 pg alum + 2 
boosts l pg MTV 
protein 
100 }Jg M'l'V protein 
and 500 pg alum 
Day after 
vaccination 
22c 
16 
25c 
20 
25c 
16 
25c 
LAI 
% reductionb 
7 
13' 
20' 
21' 
2 
19' 
Blocking-enhancing 
serum factors, 
quotient yb 
0.98 
0. 9 2 
l . 22* 
0.90* 
1. 09 
l. 02 
l .19 * 
Membrane fluorescence 
positive serum 
dilution 
16 
8 
16 
2 
2 
16 
a Controls were negative in all tests before challenge. Values after challenge: see text, page 107 
The controls were treated with alum only. 
b See Chapter 11.3.4 
c After challenge 
• Reactivity is significant (p < 0.010) 
**Difference in latency period between the vaccinated and the control group was significant (Table 27). 
Calculated 
cell kill (-) 
or gain (+)' 
-99.9** 
-12 
-50 
+40** 
% 
6. 4. lvfTV-specific immunologic reactivity of vaccinated animals 
The immunologic reactivity to MTV in vaccinated BALB/c mice 
is summarized in Table 30. Cellular immune reactivity and 
the presence of serum factors that interfere with cellular 
reactivity were estimated with the direct and the indirect 
LAI-assay, respectively. MTV-S was used as the antigen; RLV 
served as a specificity control. Anti-MTV antibodies were 
estimated by membrane immunofluorescence on MTV-positive AR 
963 cells; RLV-infected NIH 3T3 cells served as a specifi-
city control. 
BALB/c mice vaccinated with 1 pg MTV protein plus alum had 
a weak positive LA! after challenge with the tumour but 
lacked blocking factors in their sera. Tumour growth was 
considerably delayed in this group. 
In group 2 (10 pg MTV-protein plus alum) after chal-
lenge, the LA! reaction was positive, but blocking factors 
were also present; the controls also showed significant 
blocking (quotient y was 1.26). No significant protection 
against the tumour was noticed in this group. 
In group 3, which received booster doses of virus 
protein, the LAI-reaction was negative after challenge with 
the tumour, but, in contrast to the control group, no 
blocking factors were found in the sera. A slight increase 
in survival was observed in this group. 
In the last group, which received a high dose of vac-
cine (100 pg), the LAI-reaction became negative after chal-
lenge with tumour cells and blocking factors appeared in 
the sera. Tumour growth was significantly accelerated in 
this group. 
Before grafting, the control animals of all groups had 
no antibodies in their sera and they did not show LAI reac-
tivity or influence of serum factors on cellular immunolo-
gy. 
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Table 31 
IMMUNOLOGIC REACTIVITY IN DBA£ MICE AFTER TREATMENT WI'l'H AN'l'IGEN AND ALUMa 
Group Vaccines 
no. 
1 pg disrupted virus 
and 5 ).lg alum 
10 pg disrupted virus 
and 50 ,ug alum 
3 0.1 pg MTV protein 
and 0.5 ,ug alum 
l pg MTV prate in 
and 5 pg alum 
1 pg MTV protein and 
5 pg alum; 1 boost of 
1 pg M'fV protein 
10 pg MTV protein and 
50 pg alum 
7 80 pg MTV protein and 
_______ l_QQ__,ug alum 
Day after 
vaccination 
15 
20 
15 
20 
13 
20 
13 
20 
17 
26c 
15 
20 
12 
LAI 
reductionb 
9' 
17. 
14. 
23' 
15. 
15. 
8 
18. 
13' 
12. 
17' 
26' 
Blocking-enhancing 
serum factors, 
quotient yb 
1. 05 
l. 03 
0. 6 7 * 
0.96 
0.94 
1.36* 
l. 09 
1 . 20* 
l. 00 
1.19 
0. 62* 
2. 00* 
1.28* 
Membrane fluorescence, 
positive serum 
dilution 
8 
16 
16 
16 
16 
8 
16 
8 
16 
32 
32 
a Controls, treated with alum only, were negative before challenge in all tests (page 109). 
b see Chapter II,3,4 
c After challenge 
Reactivity is significant (P ( 0.010) 
** Difference in survival time between vaccinated and control groups is significant (Table 28). 
Calculated 
cell kill (-) 
or gain(+),% 
-20 
-15** 
+50 
+30** 
+10** 
-15 ** 
+80 
The antivirus immunologic reactivity of DBA£ mice treated 
with antigen in combination with alum is presented in Table 
31. When virus disrupted by freezing and thawing ten times 
was used as an antigen (groups 1, 2), LA! reactivity was 
significant. Serum blocking factors were absent. After 
inoculation of a dose of 10 pg disrupted MTV, enhancing 
factors could be demonstrated in the serum. Both groups 
seemed to display a slight protection against tumour growth 
(Table 28). 
When the MTV protein fraction in combination with alum 
was used, LA! reactivity was absent only with the highest 
dose (80 pg). However, blocking factors could be demon-
strated in all groups. Positive antibody titers became 
higher with increasing vaccine dose. Except for a dose of 
10 pg, all groups showed accelerated tumour growth. 
Table 32 shows the data on immunologic reactivity of 
DBA£ mice treated with different doses of the MTV protein 
fraction and !PM. All groups, except those receiving 80 ~g 
of the protein fraction, showed good cellular immunologic 
reactivity. Serum blocking factors were present in all 
groups. Groups 1 and 2, which showed significant pro-
tection, and groups 4 and 5, which showed accelerated 
tumour growth, had low antibody titers. 
DBA£ control mice treated with alum or !PM only were 
negative before challenge in either immunologic test, but 
thereafter became positive in the LAI assay. Their sera 
then showed blocking activity. 
6.5. Discussion 
The procedure for isolation of MTV virions from tumours, 
yields electron microscopically clean virus preparations. 
The polypeptides of B-type particles isolated by this 
procedure are, after identification by PAGE, similar to 
that of tissue culture-derived virus (Teramoto et al., 
1974). However, host proteins seem to contaminate the virus 
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Table 32 
IMMUNOLOGIC REACTIVITY IN DBAf MICE AFTER TREATMENT WITH DIFFERENT DOSES OF MTV PROTEIN FRACTION AND IPMa 
Blocking-enhancing Membrane fluorescence, Calculated 
Group 
oo. 
2 
3 
4 
5 
vaccines 
0.1 ~g MTV protein 
and 50 )-!9 IPM 
1 pg MTV prate in 
and 50 pg IPM 
80 pg MTV protein 
and 50 pg IPM 
1 pg MTV protein 
and 100 pg IPM 
10 pg MTV protein 
and 100 pg IPM 
Day after 
vaccination 
13 
20 
13 
20 
12 
17 
26c 
17 
26c 
LAI, serum factors, positive 
% reductionb quotient yb dilution 
15' 1.61* 16 
9 1. 58* 64 
13' 1. 09 32 
10' 1. 23* 128 
6 1.12* 4 
18. 1.20* l 
24' 1.15 2 
21' 1. 26* 0 
28' 1. 08 16 
a Controls, treated with alum only, were negative in all tests before challenge. See text, page 109. 
b See Chapter II.3.4 
c After challenge 
Reactivity is significant (p < 0.010) 
**Difference in survival time between vaccinated and control group is significant (Table 29). 
serum cell ki 11 (-) 
or gain (+)I % 
-20** 
-10 
- 5 
+10 
+25** 
preparations: immunoelectron microscopy revealed that nor-
mal cell surface antigens are present in the virus envelope 
(Calafat et al., 1976). In addition, host proteins might be 
sticking to the virions. After absorption, little or no 
host proteins are assumed to be present in the preparation. 
Unfortunately, as became evident later, the vaccine is 
contaminated with Con A subunits. Such contamination can be 
prevented by extensive prewashing of the Con A Sepharose 
columns. Preliminary results of studies with purified MTV 
proteins indicate that the Con A subunits have no effect on 
the resistance to transplanted tumours and on immunologic 
reactivity to MTV. 
In this exploratory study, each variable such as cell 
number, protein dose, and adjuvant dose was not studied 
exhaustively; a consistent pattern emerges, however, which 
provides a basis for further detailed study: A clear dose 
effect exists for the MTV protein fraction. Protection is 
found only with low doses of MTV protein. The protective 
effect diminishes with increasing dose. High doses may 
result in enhanced tumour growth. 
Dose and kind of adjuvant are important. A high dose of 
!PM, which is protective by itself, accelerates tumour 
growth when combined with a dose of vaccine that in other 
circumstances would delay tumour growth. Obviously, when a 
strong adjuvant is used, little antigen is needed to tip 
the balance in favour of tumour acceleration. 
Results obtained with one system (MTV-0 induced mammary 
tumours in BALB/c mice) are not directly comparable to 
those obtained with another (Ll210 leukaemia in DBA£ mice). 
For example, in the first instance a low dose of vaccine 
induced clear protection, whereas in the other enhanced 
tumour growth was observed. This situation might be due 
to differences in the systems {sc solid tumour vs. ascites 
leukaemia). Also strain differences will play a role in 
immunologic reactivity: before challenge with the Ll210 
leukaemia, vaccinated DBA£ mice always developed blocking 
factors, whereas vaccinated BALB/c mice were free of them. 
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In our study, vaccination with virus disrupted by 
freezing and thawing induced protection far more efficient-
ly than did the fraction enriched for gp52, in which all 
proteins were solubilized. Charney et al. (1976) and 
Stutman (1976) obtained good results with a formalinized 
MTV preparation. The latter, however, observed tumour en-
hancement after vaccination with soluble antigens extracted 
from a C3H mammary tumour. we are presently investigating 
whether structural integrity of the virus envelope contri-
butes to protection against tumour growth. 
Protection is anticipated to result from the interaction of 
cellular immunity and humoral factors, i.e., blocking or 
enhancing factors and antibodies. 
The specificity of the LAI-assay is discussed in 
Chapter !!.3. Specificity of the antibodies, as detected by 
the membrane immunofluorescence test, was deduced from the 
negative reactions of normal mouse sera with the cell line 
AR 963 and the use of RLV-infected cells as a control, 
inasmuch as the MTV-producing cell line also shows some c-
type particles (Van Pelt et al., 1976). 
When the LAI was positive and blocking factors were 
absent, protection against tumour growth was good. The 
combination of low cellular reactivity and serum blocking 
factors has the adverse effect of faster tumour growth than 
in control animals. Predictability is more difficult for 
the two other combinations: positive LAI plus blocking 
factors or negative LAI and no blocking factors. In this 
case, antibody titer will probably play a crucial role, as 
evident in the experiments in which IPM was used as an 
adjuvant (Table 32): the groups with high antibody titers 
showed protection against tumour growth despite significant 
amounts of blocking factors. Summarizing, our results 
suggest the following relation between the immune response 
on day 20 after vaccination, and protection against or 
enhancement of the growth of a later tumour challenge: 
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LA!- reactivity serum blocking anti-MTV effect on 
factors antibodies tumour growth 
+ + protection 
+ + +++ 
+ + no clear 
+ + effect 
+ ++ enhancement 
+ 
The tumour growth acceleration induced by high doses of 
MTV protein is obviously due to the earlier appearance of 
blocking factors and poor cellular reactivity. That 
blocking factors are lacking when virus is used as an 
antigen is also of interest. 
This exploratory study shows that protection against 
transplanted tumours by an MTV-protein vaccine occurs only 
when the induction of blocking factors by the vaccination 
procedure is prevented. This is more likely to be achieved 
when a low dose of vaccine is used. Therefore, low doses of 
MTV subunit vaccines might be useful for the establishment 
of prophylaxis or at least delay of primary tumour develop-
ment in mice. 
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CHAPTER VII 
MTV PROTEIN VACCINE: INFLUENCE ON PRIMARY MAMMARY TUMOUR 
DEVELOPMENT 
The results from the vaccination studies on the induc-
tion of resistance against transplanted tumour cells 
(Chapter VI) indicate that a low dose of vaccine only may 
yield protection against primary mammary tumour develop-
ment~ For this reason, we tested the effect of a low dose 
{10 pg) without adjuvant on primary mammary tumour develop-
ment in female mice. The low MTV expressing C3Hf and 
BALB/c, and the high MTV expressing GR and BALB/cfC3H 
strains, were employed. We used the gp52-enriched MTV-S 
vaccine, that was also tested in Chapter VI; the prepara-
tion of this vaccine is described in Chapter IIiB. 
At the time of vaccination, the animals were 8 weeks of 
age; at the age of 22 weeks, they were subjected to forced 
breeding, since the resulting hormonal stimulation promotes 
tumour development. Tumours were established as described 
in Chapter II;S. 
Cellular reactivity to MTV was established with the 
direct LA! assay; reactivity to tumour cells was demon-
strated with the Winn test (Winn, 1961). Anti-MTV-anti-
bodies were detected by means of membrane immunofluores-
cence. These vaccination studies are very long lasting and 
were started 3 years ago. At that time, the role of 
blocking factors in MTV directed cellular immunity was not 
yet known to us. Therefore, the induction of blocking 
factors by the vaccination procedure has unfortunately not 
been established. 
The vaccination studies reported in chapter VI yielded no 
clear results concerning the effect of boosting on the 
induction of resistance to transplanted mammary tumours. 
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Table 33 
INFLUENCE OF VACCINATION WITH 10 pg MTV-S PROTEIN VACCINE ON DEVELOPMENT OF PRIMARY MAMMARY 
TUMOURS IN DIFFERENT MOUSE STRAINSa 
Mouse strain Tumour incidence Latent period (weeks) + SEb 
Vaccinated Controls vaccinated Controls Significance 
GR 9/ 9 (100 %) 54/54 (100 %) 36.0 + 2.7 27.1 + 1.2 0.005 < p (0.010 
C3Hf 15/39 ( 39 %) 28/90 ( 31 %) 57.7 + 4.2 76.9 + 2.5 p < 0.001 
BALB/c 39/107( 37 %) 27/90 ( 30 %) 66.9 + 3.2 77.4 + 3.1 0.010 < p < 0.025 
BALB/cfC3H 29/31 ( 94 %) 38/40 ( 95 %) 42.0 + 1.6 36.4 + 0.9 0.001 ( p(0.005 
a: design of experiments: see Chapter II.6 
b, standard error 
Therefore, it was investigated whether the administration 
of booster doses have a beneficial effect on primary tumour 
development. In these experiments, 16-week-old BALB/cfC3H 
females were vaccinated with an MTV-0 derived protein 
fraction obtained by the same purification procedure 
{Chapter II.8), that also contained approximately 60 % 
gp52. 
For the initial immunization we used a dose of 10 pg 
that was precipitated on alum. Subsequently, 0, 2 or 5 
booster doses of 1 pg unprecipitated MTV-0 protein fraction 
were injected. The animals were subjected to forced 
breeding when they were 37 weeks of age. 
Since limited numbers of mice were available, the sera 
were tested only for the presence of anti-MTV antibodies. 
7. 1. Influence of an MTV-S protein vaccine on tumov.r incidence and 
irnrrru..nity in female BALE/c., BALB/cfC3H., C3Hf and GR mice 
~ffe~t_o! ~a£cln~tlo~ ~n_t~m~u~ in£i~e~c~. A single sc 
immunization with 10 pg protein vaccine resulted in a sig-
nificant delay in tumour appearance in the high cancer 
strains GR and BALB/cfC3H. It is importent to note that the 
incidence of tumours was not decreased. In the C3Hf and the 
BALB/c strain, which normally have a moderate incidence of 
tumours appearing at a relatively old age, vaccination 
resulted in accelerated tumour development and a slight 
increase in tumour incidence. In the C3Hf strain the 
shortening of the latent period for tumour development is 
highly significant; in the BALB/c strain the rather low P-
value represents the border line of significance (table 
33) • 
For the interpretation of vaccination studies it is 
important to know whether transplantation resistance to 
syngeneic mammary tumours is a useful parameter. Therefore, 
GR and BALB/c mice vaccinated with 10 pg of the MTV-5 
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Table 34 
IMMUNOLOGIC REACTIVITY OF ANIMALS VACCINATED WITH 10 pg MTV-S PROTEIN FRACTIONa 
Mouse strain 
GR 
BALB/c 
weeks after 
vaccination 
l 
2 
3 
9 
l 
2 
3 
7 
MTV-S specific 
LAI-reactivity 
(% reduction)b 
12* 
23* 
18* 
ND** 
l 0* 
5 
7 
ND 
mammary tumour cell specific 
membrane immunofluorescence 
{positive serum dilution} 
1/ 2 
l/32 
1/ 8 
l/16 
1/ 2 
1/ 8 
1/ 8 
1/ 2 
a. Each result is obtained with pooled peritoneal cells and pooled sera from 
two mice. 
b. see Chapter II,3 
* reactivity is statistically significant {p < 0.010) 
** ND: not done 
protein vaccine and untreated control animals were inocu-
lated with 10 4 syngeneic mammary tumour cells at twenty 
days post-vaccination. Both control and vaccinated animals 
all developed tumours within 4.6 to 5.4 weeks; although the 
number of mice in every group was rather large (17-32) no 
significant difference in latent period between treated and 
untreated animals could be detected. 
!fie~t_oi ~a~cln~tlo~ ~n_t~e_i~rn~n~ ~e~p£n~e. At 
various intervals after treatment the vaccinated GR and 
BALB/c mice were tested for MTV-S specific cellular immune 
reactivity by means of the direct LAI-assay; the presence 
of mammary tumour cell-specific antibodies was established 
by means of membrane immunofluorescence on the A963 cell 
line. The tests were performed with pooled cells and sera 
derived from two mice. The results are summarized in table 
34. 
Anti-mammary-tumour cell antibodies as detected with 
the membrane immunofluorescence test appeared in somewhat 
higher titer in the GR than in the BALB/c strain. Untreated 
GR or BALB/c mice of the same age had no detectable anti-
bodies in their serum. Cellular reactivity as estimated by 
the LAI-assay was clearly stronger in the GR than in the 
BALB/c strain. No appreciable reactivity was found in the 
latter strain two weeks after vaccination. For vaccination 
studies it is important to know whether anti-MTV cellular 
immune reactivity as measured by in vitro assays is a 
measure of the induced in vivo anti-tumour cell reactivity. 
We therefore also performed the Winn-test (Winn, 1961), in 
which spleen cells are tested for their ability to suppress 
the growth of admixed tumour cells in syngeneic 
recipients. 
In the GR strain, both 25 and 5 x 10 6 spleen cells 
taken 40 days after immunization completely prevented the 
growth of 5 x 10 3 admixed MTV-P induced tumour cells. 
Normal GR spleen cells had no inhibitory effect on the 
growth of transplanted mammary tumours; tumour incidence 
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was 100 %. The average latency period was 4.5 weeks in the 
case of 5,000 normal spleen cells to 1 tumour cell and 5.0 
weeks in the case of 1000 normal spleen cells to 1 tumour 
cell. Each group consisted of 10 mice; the observation 
period was 5 months. 
Spleen cells from vaccinated BALB/c mice, however, only 
partially inhibited the growth of 
(fig. 15ai b). As to be ex?ected, 
a tumour induced by WI'V-0 
the inhibitory effect was 
>00 ;· / 
"'/---· // .....•. -··············· 
, ... ·---&<:: ............... .... 
," ··········· .. 
60 
40 .... •·• 
20 b 
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Figure 15: 
Results of the Winn-assay with spleen cells from vaccinated BALB/c mice 
Spleen cells were taken forty days after vaccination with 10 llg MTV-S 
protein fraction, and mixed with MTV-0 induced tumour cells at differ-
ent ratios. Then the mixtures were injected sc into syngeneic reci-
pients. The figure represents the tumour incidence in the recipients: 
A. The spleen cell : tumour cell ratio was 5000 : 1. -----: spleen 
cells from vaccinated mice; -----: spleen cells from normal mice. 
B. The lymphoid cell : tumour cell ratio was 1000 : 1 ...... : T-cell-
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enriched spleen cells from vaccinated mice; -----: spleen cells 
from vaccinated mice. 
more pronounced when the greatest number of spleen cells 
was given. When a T-cell-enriched spleen cell fraction was 
mixed with the tumour cells, the inhibitory effect was 
slightly increased, which might indicate that T cells play 
a crucial role in the mammary tumour cell directed cellular 
immune reactivity {fig. 15b). 
7.2. Influence of different vaccination schemes on primary tumour 
development and antibody level in the BALB/cfC3H strain 
Female BALB/cfC3H mice, which are naturally chronically in-
fected with MTV-S, were vaccinated with the MTV-0 protein 
fraction. For the primary immunization 10 ng of the protein 
fraction precipitated on alum was administered sc. In addi-
tion, one group received ip two booster doses, and another 
group 5 booster doses of 1 ~g unprecipitated MTV-0 protein. 
The first booster injection was given at one week after the 
primary immunization; thereafter, the injections were given 
with two-weekly intervals. The control animals did not 
receive any treatment. The results are summarized in table 
35. 
Since in these experiments the animals were subjected 
to forced breeding at a later age {37 weeks) than in the 
other experiments, the tumour age was considerably higher. 
The results clearly demonstrate that a single immunization 
with 10 ~g MTV-0 protein precipitated on alum causes a con-
siderable decrease in primary tumour incidence {p ( 0.005). 
Booster doses have no favourable effect. 
At various intervals after vaccination all animals of 
the experimental groups were bled from the retra-orbital 
plexus; the sera of each group were pooled and tested for 
anti-mammary tumour cell antibodies by membrane immuno-
fluorescence. The results, demonstrated on figure 16, 
indicate that antibody titer increases as a result of 
booster injections. 
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Table 35 
INFLUENCE OF INJECTION OF 10 M9 MTV-0 PROTEIN VACCINE PRECIPITATED ON ALUM, WITH 
OR WITHOUT ADDITIONAL BOOSTER DOSES, ON PRIMARY MAMMARY TUMOUR DEVELOPMENT IN 
BALB/cfC3H 
Treatment 
none 
10 pg MTV-0 protein and alum 
10 pg MTV-0 protein and alum; 2 booster 
doses of 1 pg MTV-0 protein 
10 pg MTV-0 protein and alum; 5 booster 
doses of 1 pg MTV-0 protein 
a standard error 
tumour incidence 
10/10 (100 %) 
5/13 39 %) 
8/18 ( 44 %) 
5/ 9 ( 56 %) 
latent period 
(weeks) .:!:_ SEa 
56.1 + 0.9 
55.2 + 3.2 
53.3 + 1.5 
52.6 + 0.2 
Figure 16: 
l/64 
l/32 
:.0 l/16 
-
0 
'I" 
-
1 
I I I I I 
I I 
Anti-MTV antibody levels in BALB/cfC3H mice after different vaccination 
schedules 
Anti-MTV antibodies were established by means of membrane immunofluor-
escence on MTV-positive cells. RLV-infected cells served as a specifi-
city control. The results were obtained with pools of sera derived from 
at least 9 animals. All mice received a sc injection with 10 pg MTV-0 
protein precipitated on alum. 
-----: mice received no further treatmenti ..... : mice received two 
additional booster doses of 1 ~g unprecipitated MTV-0 protein fractioni 
-----: mice received five additional booster doses of 1 ~g unprecipi-
tated MTV-0 protein fraction. Arrows indicate times of booster doses. 
? . 3. Discussion 
In the high mammary cancer strains GR and BALB/cfC3H immu-
nization with a dose of 10 ~g MTV-S protein vaccine induces 
a delay in primary tumour development of 9.0 and 7.5 weeks, 
respectively. For the GR strain, this is in accord with 
earlier findings using live virus (Van der Gugten and 
Bentvelzen, 1969). However, in the C3Hf strain, which nor-
mally produces tumours at a moderate incidence and at a 
late age, vaccination leads to significant acceleration of 
19.2 weeks in tumour appearance. In the BALB/c strain, an-
other low MTV expresser, tumours also appeared considerably 
earlier (10.5 weeks). 
Since the BALB/c and BALB/cfC3H strains are very close-
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ly related genetically, the different response to vaccin-
ation is probably due to the virological status. It seems 
likely that, only in the case of abundant and early virus 
production by the recipients, vaccination can result in a 
delay in primary tumour development. The induction of delay 
in tumour development in the GR strain by a MTV-S vaccine 
has been ascribed to antigenic differences between the 
immunogen and the endogenous MTV-P (Van der Gugten and 
Bentvelzen, 1969). By means of competitive radioimmunoassay 
it has recently been demonstrated that indeed MTV-S and 
MTV-P are antigenically distinct (Teramoto et al., 1977). 
However, since BALB/cfC3H mice carry the exogenous MTV-S, 
the effect of the MTV-S protein vaccine in this strain 
cannot be ascribed to immunological differences between MTV 
strains. 
The MTV-0 protein fraction precipitated on alum was 
highly protective in BALB/cfC3H mice. Like in the vaccin-
ation studies on the induction of transplantation 
resistance (Chapter VI), no favourable effect of booster 
doses could be observed. 
In the Winn test, spleen cells of GR mice treated with 
10 ~g MTV-S protein fraction caused prevention of the 
growth of admixed tumour cells, whereas cells of BALB/c 
mice that had received the same treatment only induced a 
delay of growth of admixed tumour cells. GR peritoneal 
cells also showed a higher and longer-lasting reactivity in 
the direct LA! assay than the cells of BALB/c mice. It 
seems that good cellular immune reactivity is associated 
with a delay in tumour appearance. The finding that T cell-
enriched cell populations are somewhat more active in 
inhibiting the growth of tumour cells than unfractioned 
spleen cells in vivo is in agreement with the in vitrQ 
findings that the MTV directed cellular immune reactivity 
is T cell dependent (Chapter IV). 
After vaccination, mice of the GR strain also developed 
somewhat higher antibody titers than mice of the BALB/c 
strain. BALB/cfC3H mice treated with the MTV-0 protein 
124 
fraction precipitated on alum developed moderate levels of 
antibodies; after boosting, however, the antibody titers 
increased, which was not correlated with a better 
protection. This phenomenon might be explained by the 
induction of antigen-antibody complexes (Chapter V). 
From these studies it became evident that transplant-
ation resistance is not a very sensitive indicator for 
prophylaxis against spontaneous tumour development. There 
is another discrepancy from these results and the earlier 
findings using the same MTV-S protein fraction {Chapter VI) 
that makes the use of transplantation resistance as a 
measure questionable: in these earlier studies 1 Mg of the 
protein fraction in combination with alum was protective 
against a subsequent tumour challenge in BALB/c mice, 10 pg 
and alum had no clear effect, and higher doses caused 
enhancement of the transplanted tumours. A dose of 10 pg 
without any adjuvant can be considered as rather low; 
nevertheless it causes clear enhancement when primary 
tumour development is studied. An obvious difference 
between these vaccination experiments is the time between 
vaccination and tumour development; the length of this 
latency period is likely to influence results of 
vaccination studies. 
This time factor may be important for the immune status 
at the time of tumour development. It is possible that the 
cellular immune response to MTV induced by the vaccination 
is transient, like in nontumorous mice of high cancer 
strains (Gilette and Lowery, 1976) and in tumour bearing 
mice (Chapter III). Mice of the GRand BALB/cfC3H strains 
may benefit from the induced temporary cellular reactivity 
delaying tumour development. If, however, vaccination also 
induces a persistant antiviral response at the humoral 
level, this may result in the continuous production of 
blocking factors, which affect the specific as well as the 
aspecific cellular immune response, thus resulting in en-
hanced tumour development in strains with a very long 
latent period. 
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CHAPTER VIII 
GENERAL DISCUSSION 
In view of the existence of natural cellular and humoral 
MTV-specific immune responses in various categories of 
healthy mice, the choice of ''normal'' (i.e. unresponsive) 
control animals remains a problem in immunological studies. 
For the studies concerning the reproducibility of immuno-
logic assays (Chapter II), the immunologic events during 
tumour growth {Chapter III and V) and the role of spleen 
cell subpopulations in MTV-directed cellular immunity 
(Chapter IV) there was a need for absolutely unresponsive 
normal control animals. Therefore, in these studies we used 
6-8-week-old males. To evaluate the immunologic effect of a 
given vaccination scheme, it was necessary to use female 
age-matched (8-15 weeks old) control animals in these 
experiments (Chapter VI and VII). We never found specific 
anti-MTV immune responses in our normal control animals. 
Ihle et al. (1976) using the RIA, report that pooled sera 
from 6 to 12-week-old GR males are negative, whereas GR 
females are positive. Pooled sera from female 8 to 12-week-
old BALB/cfC3H mice were positive only in a low dilution~ 
the low MTV-expressors developed antibodies at a very much 
later age. In view of these results, it is not surprising 
that our normal control animals all gave negative results 
with the far less sensitive membrane immunofluorescence 
method. 
Except for Blair's group (Blair, 1976), most studies on 
cellular anti-MTV reactions revealed that before tumour de-
velopment lymphoid cells of high MTV-expressors do not 
respond to MTV, whereas cells of low MTV expressers some-
times yield positive results (Lopez et al., 1976; Sigel et 
al., 1976; Gilette and Lowery, 1976). 
As a low MTV expresser, we mostly used BALB/c mice. The 
aforementioned investigations are mostly performed with the 
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American BALB/c subline, which seems to show less expres-
sion of the endogenous MTV-0 than does the Dutch BALB/c 
subline {Peter Bentvelzen, Don Fine~ personal communica-
tion). Since the expression of cellular anti-MTV responses 
is probably inversely related to MTV-expression, it is no 
surprise that we did not find cellular anti-MTV responses 
in our healthy BALB/c mice. 
A highly interesting subject in tumour immunology is 
the immune status in animals just before the tumour becomes 
clinically detectable. However, such an investigation 
requires extremely time-consuming longitudinal studies on 
mice which may develop a primary tumour within a relatively 
short period of time. Also, the need for great quantities 
of lymphoid cells in cellular immunological assays makes 
such an approach technically almost impossible. The study 
of suppressive immunological factors during tumour growth 
may, however, provide some insight into the insufficiency 
of the immune response with regard to tumour prophylaxis. 
The higher MTV expression which occurs during ageing is 
related with higher antibody titers (Ihle et al., 1976), 
whereas the cellular immune response already displays 
unresponsiveness before the tumour becomes clinically 
detectable. This unresponsiveness may possibly be induced 
by slight but persistent levels of soluble antigen-antibody 
complexes, which are known to inhibit the cellular immune 
response (Gorczinsky et al., 1975), whereas B cells can be 
inhibited only by immobilized immune complexes (Ryan et 
al., 1975). 
As has been shown in this investigation (Chapter IV) 
antigen-antibody complexes have a direct suppressive effect 
on the cellular immune system. In addition they may evoke 
unresponsiveness in an indirect manner: it has been shown 
that antibody of the IgG1 class, on forming a complex 
with antigen, can induce a long-lasting type of tolerance, 
apparently mediated by suppressor T cells specific for the 
antigen. These suppressor T cells may affect either T or B 
cells (Waksman, 1977). 
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The situation in MTV-infected mice seems to mimic the 
chronic infection with lymphocyte choriomeningitis virus in 
mice: the latter do not express cellular reactivity to the 
virus (Citrak and Lehmann-Grube, 1974), but virus-antivirus 
immune complex deposits have been found in the renal glo-
meruli (Olding et al., 1976). 
The present investigation confirms the results of other 
authors on the presence of anti-MTV antibodies in tumour 
bearing mice; humoral reactivity was higher in the high-
MTV-expressing BALB/cfC3H strain than in the low MTV 
expresser BALB/c. The finding that unresponsiveness at the 
cellular level is abolished when the tumour develops is 
also in accordance with earlier findings (Lopez et al., 
1976). Unresponsiveness may wane because either new 
receptors or new cells are generated, or because excess 
antigen paralyses a suppressive T cell system. 
In this investigation, a good agreement was found 
between reactivity as measured by the LAI, the LS and the 
Winn assays; this indicates that both LAI and LS reactivity 
may be trustworthy in vitro parameters for the in vivo 
cellular immune response. 
Anti-MTV reactivity was found to be T cell-dependent. 
In addition, we found that adherent cells play a crucial 
role: in the LAI-test (and probably also in the LS test), 
they provide the first signals for reactivity to MTV. 
A new aspect that arises from this study is the 
observation that cellular immunity declines sharply when 
the tumour reaches a weight above approximately 2 grams, 
but recovers partly when tumour growth continues. We found 
three suppressive mechanisms that all exert their influence 
very early after tumour development: (i) adherent suppres-
sor cells; {ii) blocking factors in the serum; and (iii) an 
inhibitory substance covering the spleen cells. Evidence 
was presented that the two latter factors are antigen-
antibody complexes. In addition to those factors, other 
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authors have provided evidence for the existence of T 
suppressor cells (Roubinian et al., 1976). 
Thus, the following immunologic events are likely to occur: 
When the tumour starts to develop, only low levels of 
antigen-antibody complexes will be present. Antigen levels 
increase steeply just before the development of the tumour 
(Ritzi et al., 1976); this results in the adequate 
triggering of lymphoid cells. This causes a relatively good 
cellular immune response when the tumour is still small. 
However, the antibodies in the circulation bind to the 
tumour cells and subsequently capping and shedding of the 
immune complexes takes place. Gradually, these complexes 
will be found in the entire circulation~ they will bind to 
the lymphoid cells and thus make them nonresponsive. New 
populations of cells that are generated may be the cause of 
the oscillation in reactivity seen after the tumour has 
become heavier than 3 grams; however, the original level of 
reactivity is never reached again. It must be assumed that 
the new populations of lymphoid cells are confronted with 
such an overwhelming amount of antigen-antibody complexes 
that the corresponding receptors and lymphokine acceptor 
sites are almost immediately covered. For this reason, they 
cannot become adequately stimulated. 
It is a reasonable assumption that these events will 
also affect the humoral immune response. We found a clear 
oscillation in antibody titer during tumour growth. This is 
in accord with the findings of MUller et al. (1971), who 
also found sera of some tumour bearing GR mice to be 
negative for antiviral antibodies; in case the sera were 
positive, a higher titer than in normal animals was found. 
However, the methods used (membrane immunofluorescence and 
the micro-Ouchterlony assays, respectively) are not very 
sensitive. Ihle et al. (1976) do not mention variation in 
antibody titer in tumour bearing animals, but they always 
tested pools of sera obtained from several mice. In 
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cooperation with the Frederick Cancer Research Centre, we 
tested some individual tumour bearing mice repeatedly 
during 2 months by means of the RIA and membrane immuno-
fluorescence assays; preliminary results indicate that the 
antibody titer as measured by RIA in individual tumour 
bearing mice is variable; some sera yielded even negative 
results. 
The oscillation in antibody titer observed in a longi-
tudinal study in tumour bearing animals may be due to the 
inactivation of helper T cells of the B cell system by 
soluble antigen-antibody complexes (Waksman, 1977). Pre-
cursor B cells are also known to become nonresponsive when 
confronted with large amounts of antigen (Desaymard and 
Waldmann, 1976). Mature B cells have been found to be in-
hibited only by insolubilized immune complexes (Ryan et 
al., 1975), but it is possible that the complexes aggre-
gated on other lymphoid cells will serve as such inhibi-
tors. When the blood passes the kidney, lymphocytes will 
also be confronted with the immune complex deposits in the 
renal glomeruli, which may exert their inactivating in-
fluence on the mature lymphocytes. 
Antigen-antibody complexes may also be the cause of the 
inhibition of humoral cytotoxic anti-MTV responses, which 
occurs at low dilutions in sera from tumour bearing mice 
(Stolfi et al., 1977). 
In human breast cancer patients, the cellular immune 
response was extensively studied by the group of Grosser 
and Thompson by means of the LA! assay (1975). As an 
antigen, they used KCl extracts from malignant breast 
tumours. They observed that stage I breast cancer patients 
showed positive cellular immune responses to breast cancer 
antigens, whereas in patients with disseminated disease 
immune reactivity is generally impaired. The decrease in 
reactivity in late stage breast cancer patients has also 
been observed when the migration inhibition (Black et al., 
1974; Cochran et al., 1974) and the mixed lymphocyte 
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culture (Blomgren and Baral, 1977) tests were used. With 
the LA! assay, it was demonstrated that reactivity of the 
lymphoid cells in breast cancer patients with decreased 
reactivity was increased after slight trypsinization 
(Grosser and Thompson, 1976), which mimics our results in 
mice bearing mammary tumours. 
It has been found that the erythrocyte receptor sites 
of T lymphocytes from breast cancer patients are masked; 
this could be reversed by papain treatment (Whitehead et 
al., 1976). As in the mouse system, cellular immune reac-
tivity could be inhibited by factors in the serum of human 
breast cancer patients; this has been demonstrated by means 
of the LA! (Flores et al., 1977) and the migration inhi-
bition (Rieche et al., 1976) assay. Pleural effusions from 
breast cancer patients contain complexes of breast-cancer-
associated antigen and corresponding antibodies (Gorsky et 
al., 1977). Also tumour antigen has been detected in their 
serum (Flores et al., 1977). In addition, an antigen that 
reacted to gp52 of the murine MTV has been demonstrated on 
lymphocytes from human breast cancer patients (Wiseman et 
al., 1977}. 
In view of the fact that human breast cancer cells show 
capping of antigens upon incubation with antiserum and 
subsequent shedding of these antigen-antibody complexes 
(Nordquist et al., 1977), it is likely that the immunologic 
events that take place during tumour growth in the human 
and the mouse system are basically the same. 
Mice are able to respond immunologically to MTV, but this 
response is insufficient to prevent the development of a 
tumour. Therefore, it was investigated whether tumour pro-
phylaxis could be obtained by increasing the anti-MTV im-
mune response before tumour development. Since by vaccin-
ation with whole virus potentially oncogenic material would 
be introduced into the host, the seemingly best approach 
would be the use of purified viral proteins, which are ex-
pressed on the tumour cell membrane. However, in 1975, when 
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the vaccination studies were started, purified gp52 was not 
available; therefore, vaccination studies were performed 
with an MTV-derived protein fraction which contained ap-
proximately 60 % gp52. 
Since studying the influence of vaccination on primary 
tumour development is very time-consuming, the majority of 
our vaccination experiments have been carried out by 
measuring the induction of resistance to transplanted 
mammary tumours. From our results, four main conclusions 
can be drawn: 
(1} mouse strain differences influence the result of a 
given vaccination procedure; besides from immune response 
gene differences, this probably results also from a dif-
ferent MTV-expression, and subsequently, a different status 
of natural immune response to MTV; 
(ii) there is a clear dose-dependency, in that a low 
dose of antigen will tend to give protection, and a high 
dose results in enhancement of tumour development; 
(iii) structure of the antigen is important; 
(iv) tumour enhancement after vaccination is associated 
with the induction of factors in the serum that block the 
cellular immune response by the vaccination procedure. 
Our preliminary results indicate that vaccination with 
purified gp52 so far does not seem to have a different 
effect than the administration of the aforementioned crude 
preparations. 
It is highly important to device vaccination procedures 
which circumvent the induction of blocking factors. It will 
be mandatory to stimulate only the cellular immune res-
ponse, and to keep antibody formation as low as possible. 
Induction of cellular immunity depends on the structure and 
hydrophobicity of the antigen (Wilkinson, 1976); we there-
fore will study the possibility of alteration of the anti-
gen by conjugating lipid to purified gp52, a procedure that 
is known to enhance cellular immune responses (Hunter and 
Strickland, 1975). Non-virion, but virus-coded TSSA( 's) are 
expressed on the membrane of mammary tumour cells. we are 
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presently investigating whether such proteins exist in the 
MTV-system. When it is possible to purify them, they might 
be suitable for vaccination against mammary tumour develop-
ment. 
The majority of authors who studied cellular and humoral 
anti-breast-cancer immunity in patients observed that a 
certain proportion of healthy women also show positive 
reactions. Apparently, natural anti-breast-cancer responses 
also occur in the human species. It is therefore not 
excluded that specific or nonspecific immune stimulation 
involves the risk of tumour enhancement. Until now no 
tumour enhancement after immune therapy in breast-cancer-
patients has been reported (Nathanson, 1977). However, it 
remains an open question whether the clinical trials have 
been sufficiently accurate to establish such effects: it is 
unavoidable that groups of patients are rather 
heterogenous, and this may obscure a tumour-enhancing 
effect after immune therapy in individual patients. 
When no method is found to prevent the induction of 
blocking factors, vaccination in humans 1 as well as immune 
therapy, will become considerably complicated. For both 
procedures, it will become necessary to establish first 
under which conditions of anti-breast cancer immune re-
sponse, immune manipulations may give favourable results. 
Such experiments on vaccination will be, in view of the 
anticipated long-latency period of breast cancer, extremely 
long-lasting. The need to carefully monitor natural immune 
responses before vaccination will limit for practical 
reasons this procedure to high-risk groups only. Since 
results of clinical trials on specific or nonspecific 
immune stimulation in patients are expected to become 
available within a reasonable period of time, only immune 
therapy will then have realistic perspectives. 
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SUMMARY 
The mouse mammary tumour virus (MTV) is horizontally and 
vertically transmitted in the mouse. MTV induces mammary 
tumours and structural MTV proteins are expressed on the 
tumour cell membranes. We investigated the immunological 
events during tumour growth. In addition, it was studied 
whether protection against growth of transplanted tumours 
or primary tumour development could be induced by treatment 
with an MTV protein vaccine. 
For our studies, we used the high MTV expressing GR and 
BALB/cfC3H and the low MTV-expressing BALB/c, C3Hf and DBAf 
strains. In all strains, MTV is expressed long before 
tumour development; at that time, the mice also show anti-
MTV immune responses. Humoral responses are higher in the 
high-MTV expressers, but cellular responses are higher in 
the low MTV expressers. The cellular unresponsiveness in 
the high MTV expressers is broken when a tumour transplant 
is given. During tumour growth, both cellular and humoral 
immune responses become higher than they were previously. 
The immunologic events during tumour growth, including 
immune suppressive mechanisms, have not been extensively 
investigated in the MTV-system. 
Chapter II describes the immunological techniques that were 
applied to establish the immune response. 
The presence of anti-MTV antibodies was established 
with membrane immunofluorescence to specific target cells; 
embryonic fibroblasts were used as a control. Cellular 
immunity was investigated with the direct leukocyte ad-
herence inhibition (LA!) assay; this test is based on the 
fact that the number of cells that adhere to plastic or 
glass surfaces is reduced, when antigen is added. We also 
used the leukocyte stimulation (LS) test, in which l4c-
thymidine incorporation is taken as a measure for cell 
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proliferation in the presence of antigen. In both assays, 
Rauscher leukaemia virus (RLV) was used as a specificity 
control. 
To determine which cells were necessary for the MTV-
specific LAI-reaction, we developed the indirect LAI-assay. 
This assay proved to be more sensitive than the direct LAI-
assay. The indirect assay involves the transfer of the 
leukocyte adherence inhibition factor, (LAIF) which is 
produced by spleen cells from immune animals when they are 
cultured with antigen, to indicator cells; for the latter, 
peritoneal exudate cells from normal mice were used. Since 
there is no previous experience with the LAI-assay in the 
MTV-system, the specificity of the direct and the indirect 
LAI assays has been extensively established. 
Chapter III describes an investigation to the anti-MTV 
immune response during spontaneous tumour growth. For this 
purpose, the immune response in BALB/c, BALB/cfC3H and GR 
mice bearing tumours of varying sizes were used. Specific 
humoral immunity was found to be present on most occasions, 
but antibody titer fluctuated during tumour growth. In both 
the LS and direct LAI assays, anti-MTV reactivity peaked at 
a tumour weight of about one gram; afterwards, it almost 
completely disappeared. Reactivity increased again to about 
half of the original level when the tumour reached a weight 
of about three grams. Peak proliferation of lymph node 
cells was observed at a tumour weight somewhat higher than 
when peak proliferation of spleen cells occurred. 
Chapter IV describes a study in which the role of different 
spleen cell subpopulations in MTV directed cellular reac-
tivity was investigated. Spleen cells from immunized mice 
were treated with crude separation techniques prior to 
testing. It was established that the lymphocyte population 
which responded in vitro with proliferation in the LS assay 
in the presence of MTV were T cells. For the reaction in 
the LAI assay, both T cells and cells with adherent proper-
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ties are necessary. Cell-to-cell communication is mediated 
by soluble factors. It became established that, for the 
production of LAIF, the following sequence of incubation 
between T- and adherent cells is required: 
(1) incubation of adherent cells with MTV~ (2) transfer of 
a soluble factor, SF1 , produced by the adherent cells to 
T cells; (3) transfer of another soluble factor, SF 2 , 
released by T cells to the adherent cells. Upon this con-
tact the adherent cells release LAIF. 
Chapter V describes an investigation to the cause of the 
decline in cellular immune reactivity, that is observed 
during tumour growth. Three mechanisms that inhibited the 
MTV-specific immune response were observed: 
(i) the depression in MTV-specific proliferation was 
partly due to the presence of suppressor cells which have 
adherent properties. These suppressor cells occur early 
during tumour growth and exert their greatest influence 
when the tumour weighs 0.5 - 1.5 grams. In animals bearing 
larger tumours, the suppressor cell activity was lower. 
(ii) Reactivity of nonresponsive T-cell-enriched cell 
populations from animals bearing large tumours could be 
restored by mild trypsinization or extensive washing of the 
cells. When cells from mice immunized with MTV were incu-
bated with the wash fluid of the initially unresponsive 
cells, MTV-specific proliferation and LAI reactivity was 
inhibited. Washings of normal cells had no such effect. 
(iii) Sera from all tumour bearing animals tested 
contained factors that block cellular reactivity. 
The two latter factors appeared early after tumour 
development. They both contained MTV and anti-MTV anti-
bodies, whereas wash fluid from lymphoid cells and sera 
from normal animals were negative. These results make it 
likely that the paralysis of the immunocytes is caused by 
excess of immune complexes. 
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Chapter VI describes vaccination experiments, in which the 
induction of transplantation resistance against MTV-
containing neoplasms by treatment with a MTV-protein 
fraction that consisted for approximately 60 % of the major 
viral membrane glycoprotein gp52 was studied. The vaccine 
was derived from MTV-S. BALB/c and DBA£ mice were 
vaccinated with different doses of this vaccine. Twenty 
days after vaccination, the mice were challenged with live 
tumour cells: BALB/c with an MTV-0-induced mammary tumour, 
DBA£ with the MTV-positive leukaemia Ll210. Alum and an 
interphase material isolated from i1.ycobacterium smegmatis 
(IPM) were used as an adjuvant; control animals were 
treated with the adjuvant alone. 
In BALB/c mice treated with 1 ~g of the gp52-enriched 
protein fraction precipitated on alum, tumour development 
was delayed 10 weeks; a dose of 10 pg had no clear effect. 
A dose of 100 ~g, however, caused clear acceleration of 
tumour development: each of the vaccinated animals 
developed a tumour, as compared to 60 % of the control 
group. 
In DEAf mice low doses of the vaccine precipitated on 
alum accelerated tumour development. In general, acce-
leration was stronger when a higher dose was used. 
Fifty pg of IPM and different doses of the gp52-
enriched protein fraction in DBAf mice resulted in 
protection. In combination with 100 pg !PM, however, tumour 
development was accelerated. 
Specific cellular immune reactivity to MTV was deter-
mined by means of the direct LAI assay. Serum was tested 
for the presence of factors that either block or enhance 
the indirect LAI reaction; the presence of anti-MTV anti-
bodies was established with the membrane immunofluor-
escence test. Protection was observed when serum blocking 
factors were absent, even if cellular immune reactivity and 
antibody titer were low. When serum blocking factors were 
present, protection was observed only when it was combined 
with high antibody titers and strong cellular immunity. 
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In Chapter VII, the influence of the gp52-enriched vaccine 
on primary tumour development is described. Subcutaneous 
inoculation of a dose of 10 pg of MTV-S derived vaccine 
induced a significant delay in the appearance of primary 
mammary tumours in the high cancer strains GR and 
BALB/cfC3H; in the strains BALB/c and C3Hf, however, which 
have a moderate ~umour incidence at an advanced age, this 
treatment result~d in a slight and substantial acceleration 
respectively, of primary tumour development. The induced 
specific cellular immune reactivity after vaccination as 
measured with the in vivo Winn-test and the in vitro LA! 
assay was strongest in the GR-strain as compared to the 
BALB/c strain. The titer of antibodies to tumour cells as 
estimated by membrane immunofluorescence was also higher in 
the GR strain. 
In BALB/cfC3H mice the influence of different vaccin-
ation schemes with an MTV-0 derived protein vaccine on 
primary tumour development was studied. Before subcutaneous 
injection the vaccine was precipitated on alum. A dose of 
10 pg of this vaccine resulted in a 61 % decrease in tumour 
incidence. Two or five additional booster injections with 1 
pg of the unprecipitated protein vaccine had no beneficial 
effect, although the amount of antibodies measured was 
increased after boosting. 
In the general discussion (Chapter VIII) are discussed the 
immune state of the mice before and after the development 
of an MTV-induced mammary tumour, and the problems in 
achieving successful vaccination. The literature concerning 
the immune state in humans to breast cancer antigens is 
summarized. Many immunological aspects in man and mice show 
a striking similarity. Therefore, when immune therapy and 
vaccination in humans is taken into consideration, one has 
to pay attention to the findings in the mouse system. 
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SAMENVATTING 
In muizen wordt kanker van de melkklier veroorzaakt door 
het mammary tumour virus (MTV); dit virus wordt voor-
namelijk overbracht op de nakomelingen via de melk en/of in 
de vorm van genetische informatie. Eiwitten die deel uit-
rnaken van het MTV worden ook afgezet op de wand van de 
tumorcel. 
Wij onderzochten de anti-MTV immuunrespons gedurende de 
tumorgroei. Tevens werden vaccinatie-experimenten uitge-
voerd met een MTV-eiwitfractie; getracht werd resistentie 
op te wekken tegen getransplanteerde en spontane tumoren. 
voor dit onderzoek gebruikten wij de GR- en de BALB/cfC3H-
stamrnen, die een sterke MTV expressie en een hoge tumor-
incidentie hebben, alsrnede de BALB/c-, C3Hf- en DBAf-
starnmen, die slechts geringe hoeveelheden MTV produceren en 
waarbij de tumorincidentie laag is. 
In al deze muizenstammen wordt al MTV in het serum 
aangetroffen voordat er een tumor aanwezig is; de muizen 
vertonen dan een positieve immuunreactie tegen MTV. De 
hurnorale respons is hoger in dieren die een sterke MTV 
expressie hebben, maar de cellulaire reactie is groter in 
muizen met een zwakke MTV-expressie. Transplanteert men 
echter in stammen met een sterke MTV-expressie een tumor, 
dan vertonen de rnuizen daarna wel een cellulaire anti-MTV 
reactie. Als er een tumor aanwezig is wordt de cellulaire 
en humorale immuunrespons in alle stammen hoger dan zij 
daarvoor geweest is. Over het verloop van immuunrespons 
tijdens de tumorgroei en het optreden van immunosuppres-
sieve mechanismen is in het MTV systeem neg weinig bekend. 
Hoofdstuk II geeft een overzicht van de technieken waarmee 
de anti-MTV irnrnuunrespons in dit onderzoek werd bepaald. 
De aanwezigheid van anti-MTV antilicharnen werd bepaald met 
de indirecte mernbraan immunofluorescentie test; hierbij 
werden tumorcellen als specifieke targetcellen gebruikt en 
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embryonale fibroblasten deden dienst als controlecellen. De 
cellulaire immuniteit werd bepaald met de directe leukocyt 
adherentie inhibitie (LAI) test; deze test is gebaseerd op 
bet principe dat het aantal cellen dat zich vasthecht aan 
glas of plastic specifiek verminderd is als er antigeen 
wordt toegevoegd. Tevens gebruikten wij de leukocyt 
stimulatie (LS) test, waarbij de incorporatie van 14c-
thymidine in het cellulaire DNA als maat wordt genomen voor 
de mate van celproliferatie in de aanwezigheid van een 
antigeen. In beide testen werd als specificiteitscontrole 
Rauscher leukemie virus (RLV) gebruikt. 
Om te kunnen bepalen welke celsubpopulaties een rol 
speelden bij de cellulaire anti-MTV immuun respons werd de 
indirecte LAI test ontwikkeld. Deze test bleek bovendien 
gevoeliger te zijn dan de directe methode. In de indirecte 
test wordt de leukocyt adherentie inhibitie factor (LAIF), 
die door immune miltcellen in aanwezigheid van antigeen 
wordt geproduceerd, overgebracht op indicatorcellen; 
hiervoor werden peritoneaalcellen van normale muizen 
gebruikt. Aangezien de LAI-test nog niet eerder in het MTV-
systeem gebruikt is, hebben wij de specificiteit van de 
directe en de uitgebreid onderzocht. 
Hoofdstuk III beschrijft de resultaten van een onderzoek 
naar de relatie tussen de tumorgroei en de expressie van de 
anti-MTV immuun respons. Als proefdier werden BALB/c-, 
BALB/cfC3H- en GR-muizen met een spontane melkkliertumor 
gebruikt. Meestal waren er specifieke anti-MTV antilichamen 
in het serum aanwezig, maar de antilichaamtiter fluctueerde 
gedurende de groei van de tumor. De cellulaire immuniteit 
tegen MTV, die met de directe LAI en de LS test werd 
vastgesteld was het hoogste als de tumor een gewicht had 
van ongeveer 1 gram; daarna verdween de reactiviteit bijna 
geheel. Als de tumor een gewicht van drie tot vier gram had 
bereikt, herstelde de cellulaire immuniteit zich gedeelte-
lijk. Lymfkliercellen bereikten de hoogste proliferatie bij 
een iets boger tumorgewicht dan miltcellen. 
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Hoofdstuk IV beschrijft een onderzoek, waarin werd nagegaan 
welke subpopulatie van de lymfo1de cellen verantwoordelijk 
was voor de cellulaire anti-MTV reactiviteit. Hiertoe 
werden miltcellen van geimmuniseerde dieren voor het uit-
voeren van de test behandeld met celscheidingstechnieken. 
In de LS test bleken alleen de T-cellen te prolifereren na 
incubatie met MTV. Voor de MTV-specifieke LAIF productie 
waren zowel T cellen als cellen met adherente eigenschappen 
noodzakelijk. De communicatie tussen deze celpopulaties 
werd tot stand gebracht door oplosbare factoren. Nader 
onderzoek wees uit dat aan de LAIF-productie waarschijnlijk 
de volgende reeks gebeurtenissen vooraf gaat: (1) als eel-
len met adherente eigenschappen met MTV geincubeerd worden, 
produceren zij een oplosbare factor, SF1 ; (2) als SF 1 
in kontakt komt met T cellen, produceren deze laatsten een 
andere oplosbare factor, SF 2 ; (3) als SF 2 op cellen met 
adherente eigenschappen wordt overgebracht, produceren 
dezen LAIF. 
Hoofdstuk V beschrijft een onderzoek naar de oorzaken van 
de verminderde cellulaire reactiviteit, die gedurende de 
tumorgroei optreedt. Er werden drie suppressorfactoren 
gevonden die de cellulaire anti-MTV reactiviteit gedurende 
de tumorgroei remmen: 
(1) de depressie in MTV-specifieke celproliferatie werd 
gedeeltelijk veroorzaakt door de aanwezigheid van suppres-
sorcellen met adherente eigenschappen. Deze suppressorcel-
len zijn reeds aanwezig als de tumor nog klein is; hun 
grootste invloed werd gemeten bij een tumorgewicht van 0,5 
- 1,5 gram. In dieren met grotere tumoren was de invloed 
van de suppressorcellen minder. 
{2) T-cel verrijkte subpopulaties van muizen met grate 
tumoren, die niet positief waren in de LS test, vertoonden 
een MTV-specifieke reactie nadat zij erg vaak gewassen 
waren of een milde trypsinisatieprocedure hadden ondergaan. 
De wasvloeistof van de niet-responderende cellen van 
tumordragers remde de MTV-specifieke LAIF-productie en LS-
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activiteit van immune cellen na preincubatie. 
(3) De sera van alle tumordragende dieren die getest 
werden, bleken factoren te bevatten die de cellulaire 
immuniteit tegen MTV remmen. 
De inhiberende werking van serum en wasvloeistof van 
lymfoide cellen van tumordragers werd reeds bij dieren met 
kleine tumoren aangetroffen. Beiden bleken zowel MTV als 
anti-MTV antilichamen te bevatten; bij serum en wasvloei-
stof van lymfoide cellen van dieren zonder tumor, die niet 
remmend werkten, was dit niet het geval. Deze resultaten 
maken het aannernelijk dat de lymfoide cellen geinhibeerd 
worden door een overmaat aan antigeen-antilichaam com-
plexen. 
Hoofdstuk VI beschrijft de resultaten van vaccinatie ex-
perimenten, waarbij als vaccin een MTV-eiwitfractie, die 
voor ongeveer 60 % uit het grootste virale membraan eiwit, 
gp52, bestond, gebruikt werd. Het effect van de vaccina-
tieprocedures werd getest door de resistentie tegen ge-
transplanteerde tumoren te meten. Twintig dagen na vacci-
natie werden gevaccineerde BALB/c en DBAf muizen ingespoten 
met respectievelijk een door MTV-0 geinduceerde melkklier-
tumor en de MTV-positieve Ll210 leukemie. Als adjuvant werd 
aluin gebruikt 1 en een stof die geisoleerd was uit 
Mycobacterium segmatis {IPM). 
In BALB/c-rnuizen die met 1 ~g van de op aluin gepreci-
piteerde MTV-fractie gevaccineerd waren, was de tumorop-
komst 10 weken vertraagd; een dosis van 10 ~g had geen 
duidelijk effect op de groei van de getransp1anteerde 
tumoren. Een dosis van 100 ~g veroorzaakte echter een 
duide1ijke versne1ling van de tumoropkomst: 100 % van de 
gevaccineerde, doch s1echts 60 % van de contro1edieren 
ontwikkelden een tumor binnen de observatieperiode. In 
DBAf-muizen veroorzaakte lage doses van het op a1uin ge-
precipiteerde vaccin reeds verkorting van de latentietijd; 
over het a1gemeen was deze versne1ling sterker naarmate de 
dosis die voor vaccinatie gebruikt werd, hoger was. 
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Als DBAf rnuizen gevaccineerd werden met 50 pg IPM in 
combinatie met verschillende doses van de MTV-eiwit fractie 
was de tumorontwikkeling vertraagd. Gebruikte men echter 
100 M9 IPM, dan was de tumorgroei versneld. 
Specifieke cellulaire anti-MTV reactiviteit en de 
aanwezigheid van blokkerende factoren in het serum na 
vaccinatie werd vastgesteld met de LAI test. Anti-MTV 
antilicharnen werden bepaald met de membraan imrnunofluores-
centie test. De afwezigheid van blokkerende factoren in het 
serum was gecorreleerd met protectie tegen turnorontwikkel-
ing, zelfs als de cellulaire en humorale anti-MTV reacties 
erg laag waren. Waren blokkerende serumfactoren wel aan-
wezig, dan trad protectie alleen op indien dit gecombineerd 
was met hoge cellulaire reactiviteit en met hoge antilich-
aamtiters. 
Hoofdstuk VII beschrijft een onderzoek waarbij de invloed 
van het voor gp52 verrijkte vaccin getest werd op de ont-
wikkeling van spontane melkkliertumoren. In de BALB/cfC3H-
en de GR-starn, die beiden een hoge tumorincidentie hebben, 
veroorzaakte subcutane injectie van 10 pg van een van MTV-S 
afkomstig vaccin een significante vertraging in tumoront-
wikkeling. In de BALB/c- en C3Hf-stamrnen echter, die beiden 
een lage tumorincidentie hebben, had vaccinatie met de-
zelfde dosis een versnelling van tumorontwikkeling tot ge-
volg. Deze versnelling was alleen in de C3Hf-stam signifi-
cant. 
De door de vaccinatie opgewekte MTV-specifieke cellu-
laire en humorale immuunrespons was boger in de GR- dan in 
de BALB/c-stam. 
De invloed van verschillende vaccinatieschema•s op de 
ontwikkeling van primaire mamrnatumoren werd bepaald in de 
BALB/cfC3H-stam. Hiervoor werd een voor gp52 verrijkt 
vaccin gebruikt dat afkomstig was van MTV-0. Subcutane 
injectie van dit vaccin in combinatie met aluin veroor-
zaakte een verrnindering van 61 % in tumorincidentie ver-
geleken met onbehandelde controle dieren. Twee andere 
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groepen muizen ontvingen na deze injectie nog respectie-
velijk 2 en 5 intraperitoneale booster injecties met 1 ~g 
van het MTV-0 vaccin; deze behandelingen resulteerden 
echter niet in een sterkere verlaging van de tumorinciden-
tie. Niettemin trad na de booster injecties een verhoging 
van de antilichaamtiter op. 
In de algemene discussie (Hoofdstuk VIII) wordt de immuun-
status bij rnelkklierkanker in het muizesysteem en de pro-
blemen die bij vaccinatie optreden, besproken. Ook worden 
de literatuurgegevens over de tegen borstkankerantigenen 
gerichte immuunstatus bij de mens sarnengevat. Veel immuno-
logische gegevens in beide species vertonen een treffende 
overeenkomst. Bij het overwegen van immunotherapie en 
vaccinatie in de humane praktijk dient men derhalve 
rekening te houden met de bevindingen in het muizesysteem. 
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ADCC 
cpm 
D 
FA 
FCS 
Fe LV 
FITC 
FOCMA 
ABBREVIATIONS 
antibody dependent cellular cytotoxicity 
counts per minute 
daltons 
Freund adjuvant 
Foetal calf serum 
Feline Leukaemia Virus 
fluorescein isothiocyanate 
Feline oncornavirus associated cell membrane 
antigen 
FLV Friend leukaemia virus 
iAp intracytoplasmatic A particles 
ip intra-peritoneal 
IPM interphase material isolated from Mycobacterium 
LAI 
LAIF 
LS 
MER 
uv 
smegmatis 
leukocyte adherence inhibition 
leukocyte adherence inhibition factor 
leukocyte stimulation 
derivative of BCG 
ultraviolet 
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